text
stringlengths 0
197k
|
|---|
The investigators used several assessment tools including Hodkinson's Mental Test, Montreal Cognitive Assessment, Stroop Test, Trail Making Test, and the Turkish World Health Organization Quality-of-Life Scale. conditions: Healthy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 56 type: ACTUAL name: Square Stepping Exercise measure: Change on Cognitive Functions from Base on the Montreal Cognitive Assessment In 6 Weeks measure: Change on Cognitive Functions from Base on the Stroop Test In 6 Weeks measure: Change on Cognitive Functions from Base on the Trail Making Test In 6 Weeks measure: Change on Quality of Live from Base on the World Health Organization Quality-of-Life Scale Turkish version In 6 Weeks sex: ALL minimumAge: 65 Years maximumAge: 75 Years stdAges: OLDER_ADULT facility: Pamukkale University city: Denizli country: Turkey lat: 37.77417 lon: 29.0875 hasResults: False |
<|newrecord|> nctId: NCT06383897 id: HS-10398-101 briefTitle: Phase 1 Study in Healthy Participants and Participants With Kidney Dysfunction overallStatus: NOT_YET_RECRUITING date: 2024-05-31 date: 2025-01-31 date: 2025-01-31 date: 2024-04-25 date: 2024-04-25 name: Jiangsu Hansoh Pharmaceutical Co., Ltd. class: INDUSTRY briefSummary: A randomized, double-blind, placebo-controlled, dose-escalation clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and the impact of food on pharmacokinetics of oral HS-10398 in Chinese healthy participants, and a clinical trial to assess the pharmacokinetic characteristics of oral HS-10398 in Chinese participants with kidney dysfunction conditions: Healthy studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 116 type: ESTIMATED name: HS-10398 name: HS-10398 Placebo measure: Incidence and severity of adverse events (AEs) measure: Serious adverse events (SAEs) measure: Observed maximum plasma concentration (Cmax) measure: Time to reach maximum plasma concentration (Tmax) measure: Elimination Halflife (T1/2) measure: Apparent clearance（CL/F） measure: Apparent Volume of Distribution（Vd/F） sex: ALL minimumAge: 18 Years maximumAge: 64 Years stdAges: ADULT facility: The Affiliated Hospital of Qingdao University city: Qingdao country: China name: Xiaolei Zhang role: CONTACT phone: 0532-82912611 email: [email protected] lat: 36.06488 lon: 120.38042 hasResults: False |
<|newrecord|> nctId: NCT06383884 id: 2024-02-134 briefTitle: Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2027-04-30 date: 2029-04-30 date: 2024-04-25 date: 2024-04-25 name: Samsung Medical Center class: OTHER briefSummary: The NRG1 gene is located on chromosome 8 (8p12 region) and encode NRG1. NRG1 gene is translated to generate six different proteins (I-VI) and at least 31 isoforms. NRG1 proteins are structurally related to EGF and contain an EGF-like motif that binds and activates ErbB3 and ErbB4. Upon ligand binding, these receptors form homodimers or heterodimers, which results in phosphorylation of the intrinsic kinase domain, and activation of the PI3K-AKT, MAPK, and other pathways. |
The overall incidence of NRG1 fusions is very rare. In many tumor types, only limited numbers of NRG1 fusion variant have been identified. By percentage, there is no organ dominance of the presence of NRG1 fusions. In an analysis of 21, 858 tumor specimens that underwent anchored multiplex PCR for targeted RNA sequencing, the prevalence of NRG1 fusions was 0.2%. Of these, CD74 was the most common partner (29%), followed by ATP1B1 (10%), SDC4 (7%), and RBPMS (5%), and most CD74-NRG1 fusions have been reported in patients with lung IMA. NRG1 fusions result in aberrant expression of the epidermal growth factor (EGF)-like domain of neuregulin-1 (NRG1) on the cell surface binds primarily to ErbB3 and ErbB4, leading to heterodimerization or oligomerization with other ERBB family members. NRG1-mediated activation of ErbB3 promotes dimerization with EGFR, ErbB2, and ErbB4. These partners phosphorylate ErbB3, forming docking sites for SH2-domain proteins, leading to pathologic activation of multiple signal transduction pathways, including the phosphoinositide 3-kinase (PI3K) pathway. Subsequently, ErbB3 expression was noted at high levels, and the proteins were phosphorylated, in fusion-positive cases. Targeting ErbB3 signaling therefore represents a promising therapeutic approach for patients with NRG1 fusion-positive malignancies. conditions: Solid Tumor, Adult studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Patritumab Deruxtecan measure: Objective response rate(ORR) measure: Duration of response (DoR) measure: Progression-free survival(PFS) measure: Disease-control rate(DCR) measure: Best percentage change in the SoD of measurable tumors measure: Overall survival(OS) measure: Incidence of Adverse events (CTCAE v5.0) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Samsung Medical Center city: Seoul zip: 06351 country: Korea, Republic of name: Se-Hoon Lee, MD, PhD role: CONTACT phone: +82-10-4579-7640 email: [email protected] lat: 37.566 lon: 126.9784 hasResults: False |
<|newrecord|> nctId: NCT06383871 id: HRS-7058-101 briefTitle: A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-06 date: 2026-06 date: 2024-04-25 date: 2024-04-25 name: Shandong Suncadia Medicine Co., Ltd. class: INDUSTRY briefSummary: This study is a multicentre, open phase I clinical study of dose escalation, dose extension and efficacy extension of HRS-7058 in subjects with advanced malignant tumour. To evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS-7058. conditions: Advanced Malignant Tumour studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 151 type: ESTIMATED name: HRS-7058 capsule/ HRS-7058 tablet measure: Dose-limiting toxicity (DLT) measure: maximum tolerated dose (MTD) measure: Phase II recommended dose (RP2D) measure: Safety endpoints: adverse events (AE) measure: Efficacy endpoints: Objective response rate (ORR) assessed based on RECIST v1.1 criterion measure: Efficacy endpoints: duration of response (DoR) assessed based on RECIST v1.1 criterion measure: Efficacy endpoints: disease control rate (DCR) assessed based on RECIST v1.1 criterion measure: Efficacy endpoints: progression-free survival (PFS) assessed based on RECIST v1.1 criterion measure: Efficacy endpoints: overall survival (OS) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06383858 id: [2023] Ethics Review NO.151 briefTitle: The Project of Gestational Hypertension and Preeclampsia Screening and Prevention Center overallStatus: RECRUITING date: 2023-08-01 date: 2028-12-31 date: 2028-12-31 date: 2024-04-25 date: 2024-04-25 name: The Third Affiliated Hospital of Guangzhou Medical University class: OTHER briefSummary: Preeclampsia is the main cause of illness and death in pregnant women and fetuses. Currently, there is no effective treatment for preeclampsia in clinical practice, and the fundamental treatment is still termination of pregnancy and placental delivery. |
Therefore, early prediction of preeclampsia and targeted strengthening of high-risk pregnant women supervision, early intervention and diagnosis and treatment can greatly reduce the serious obstetric complications and perinatal maternal and fetal deaths caused by preeclampsia, which has significant social and clinical significance. conditions: Preeclampsia conditions: Maternal Deaths studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 50000 type: ESTIMATED measure: Preeclampsia measure: Premature birth measure: Fetal Growth Restriction measure: Severe complications of preeclampsia sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: FANG HE status: RECRUITING city: Guangzhou state: Guangdong zip: 510150 country: China name: FANG HE, M.D role: CONTACT phone: 13724831279 email: [email protected] name: Qingwen Nie, Master role: CONTACT phone: 15622149953 email: [email protected] lat: 23.11667 lon: 113.25 hasResults: False |
<|newrecord|> nctId: NCT06383845 id: MAS ESLI briefTitle: Comparison of Erector Spinae Plane Block vs Intravenous Lidocaine for Chronic Pain Post Mastectomy. overallStatus: ACTIVE_NOT_RECRUITING date: 2023-01-01 date: 2024-01-31 date: 2024-09-30 date: 2024-04-25 date: 2024-04-25 name: University Tunis El Manar class: OTHER briefSummary: Patients undergoing breast surgery were divided into two groups: Intravenous Lidocaine (Lido-IV) vs Erector Spinae Block (ESP). |
For Lido-IV group, patients received a loading dose of Lidocaine than a continuous infusion till the end of surgery. |
For ESP group, an ultrasound guided ESP Block was perormed before anesthetic induction. |
Persistant pain post mastectomy was assessed by SFM-PQ score at 1, 3 and 6 months post surgery. conditions: Breast Surgery studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Erector spinae plane block VS intravenous lidocaine. primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 60 type: ESTIMATED name: Lido-IV name: ESP Block measure: Item 5 of Brief Pain inventory score (BPI Score) measure: Acute pain assessed by Simple Verbal Scale (SVS) measure: Postoperative nausea and vomiting measure: Hospital length of stay measure: DN4 questionnaire (DN4) measure: The short-form McGill Pain Questionnaire (SFM-PQ) sex: FEMALE minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tunisia city: Nabeul zip: 8000 country: Tunisia lat: 36.45606 lon: 10.73763 hasResults: False |
<|newrecord|> nctId: NCT06383832 id: 20240310_GY briefTitle: Effect of Dapagliflozin on Body Weight in Overweight Women Consuming Different Proportions of Carbohydrate Diet. overallStatus: COMPLETED date: 2021-10-28 date: 2023-12-26 date: 2023-12-26 date: 2024-04-25 date: 2024-04-25 name: Sun Jia class: OTHER briefSummary: In recent years, the prevalence of overweight and obesity has increased dramatically worldwide, of which 34.3% and 16.4% of adults in China are overweight and obese, respectively, ranking first in the world's obese population. Dapagliflozin is a sodium-glucose transporter 2 Inhibitors that inhibits glucose reabsorption and promotes urinary glucose excretion by inhibiting renal proximal tubular sodium-glucose transporter 2 Inhibitors for the treatment of type 2 diabetes mellitus. The urinary glucose excretion induced by dapagliflozin can induce weight loss through energy loss or body water loss caused by osmotic diuresis. In addition, in patients with type 2 diabetes, dapagliflozin may also induce weight loss by reducing body fat as well as subcutaneous and visceral fat.In a randomized controlled trial, type 2 diabetes patients treated with sodium-glucose transporter 2 Inhibitors lost approximately 1-3 kg. Also, sodium-glucose transporter 2 Inhibitors have shown good weight loss in obese people without type 2 diabetes. In real-world studies, a minority of type 2 diabetes patients taking dapagliflozin experienced weight gain. The American Lipid Association defines a low carbohydrate diet as the calorie intake of carbohydrates accounting for 10-25% of the total daily energy intake. In a randomized controlled trial, a low-carbon diet showed a more significant decrease in body weight, fat mass index, whole body fat, and visceral fat after 8 weeks compared to the standard diet. So, this study intends to investigate whether the weight loss effect of dapagliflozin is affected by different dietary structures. conditions: Overweight conditions: Carbohydrate conditions: Sodium-glucose Transporter 2 Inhibitors studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This study included a total sample size of 36 subjects and underwent a 12 week intervention with dapagliflozin. Then, subgroup analysis was conducted. According to the 24-hour dietary review method on the 3rd day of each week during the introduction period, the low carbohydrate group accounted for 10-25% of the total energy intake due to carbohydrates, while the non low carbohydrate group accounted for 26% or more of the total energy intake due to carbohydrates. primaryPurpose: TREATMENT masking: NONE count: 36 type: ACTUAL name: Dapagliflozin measure: Changes in Body mass index (BMI) i measure: Changes in fasting blood glucose. measure: Changes in waist circumference. measure: Changes in insulin resistance index. measure: Changes in waist-to-hip ratio. measure: Changes in abdominal circumference. measure: Changes in Blood triglycerides measure: Changes in total cholesterol measure: Changes in low-density lipoprotein、high-density lipoprotein measure: Changes in body fat percentage. measure: Changes in subcutaneous fat volume. measure: Changes in body fat volume. measure: Changes in the relative abundance of gut microbiota. measure: Changes in urine. measure: Changes in β-hydroxybutyric acid. measure: Changes in muscle mass. measure: Changes in fasting insulin. measure: Changes in visceral fat volume. measure: Changes in hip circumference. measure: The incidence of adverse events. sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Zhujiang Hospital of Southern Medical University city: Guangzhou state: Guangdong country: China lat: 23.11667 lon: 113.25 facility: Zhujiang Hospital city: Guangzhou state: Guangdong country: China lat: 23.11667 lon: 113.25 hasResults: False |
<|newrecord|> nctId: NCT06383819 id: Long-Cov-III-21 briefTitle: Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19 overallStatus: COMPLETED date: 2022-04-08 date: 2023-12-31 date: 2023-12-31 date: 2024-04-25 date: 2024-04-25 name: NPO Petrovax class: INDUSTRY briefSummary: The goal of this clinical study is to evaluate the efficacy and safety of Longidaza®, lyophilizate for preparation of solution for injection, at a dose of 3000 IU compared to placebo in the treatment of adult patients with residual changes in the lungs after COVID-19 infection conditions: Post-Acute COVID-19 Syndrome conditions: Lung Disease With Polymyositis conditions: Fibrosis conditions: Lung Diseases, Interstitial conditions: Lung; Disease, Interstitial, With Fibrosis studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 392 type: ACTUAL name: Longidaza® name: Placebo measure: Change in Forced vital capacity (FVC) (visit 4) measure: Slowing the decline in respiratory function measure: Change in FVC (visit 5) measure: The proportion of patients with an increase in the FVC (%) measure: Dynamics of hemoglobin oxygen saturation (SpO2) measure: The proportion of patients with SpO2 ≥ 93% and < 93% measure: The proportion of patients with desaturation measure: The proportion of patients with an increase in the distance of 6MWT measure: The proportion of patients with a decrease in the severity of dyspnea on the Borg scale measure: The proportion of patients with a decrease in the severity of dyspnea on the Modified Medical Research Council Dyspnea Scale (mMRC) measure: Change in cough severity on the Visual Analogue Scale (VAS) measure: Change in the assessment of the quality of life according to the European Quality of Life 5-Dimension 5-Level Questionnaire (EuroQol-5D-5L) sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: State Autonomous Healthcare Institution of the Sverdlovsk region "Aramil City Hospital" city: Aramil zip: 624000 country: Russian Federation lat: 56.6977 lon: 60.8369 facility: Private healthcare institution "Clinical Hospital "RZD-Medicine" of the city of Chelyabinsk" city: Chelyabinsk zip: 454000 country: Russian Federation lat: 55.15402 lon: 61.42915 facility: State Budgetary Healthcare Institution "Regional Clinical Hospital No. 3" city: Chelyabinsk zip: 454021 country: Russian Federation lat: 55.15402 lon: 61.42915 facility: Ural research Institute of Phthisiopulmonology city: Ekaterinburg zip: 620039 country: Russian Federation lat: 56.8519 lon: 60.6122 facility: Alliance Biomedical-Ural Group LLC city: Izhevsk zip: 426061 country: Russian Federation lat: 56.84976 lon: 53.20448 facility: Federal State Budgetary Educational Institution of Higher Education "Kazan State Medical University" of the Ministry of Health of the Russian Federation. The State Autonomous healthcare institution "Hospital for War Veterans of Kazan" city: Kazan zip: 420012 country: Russian Federation lat: 55.78874 lon: 49.12214 facility: Federal State Budgetary Educational Institution of Higher Education "Kazan State Medical University" of the Ministry of Health of the Russian Federation city: Kazan zip: 420012 country: Russian Federation lat: 55.78874 lon: 49.12214 facility: State Autonomous Healthcare Institution "Kuzbass Clinical Hospital of Emergency Medical Care named after M.A. Podgorbunsky" city: Kemerovo zip: 650000 country: Russian Federation lat: 55.33333 lon: 86.08333 facility: Medical Center Rhevma-Med LLC city: Kemerovo zip: 650070 country: Russian Federation lat: 55.33333 lon: 86.08333 facility: Federal State Budgetary Educational Institution of Higher Education "Kirov State Medical University" of the Ministry of Health of the Russian Federation city: Kirov zip: 610027 country: Russian Federation lat: 58.59665 lon: 49.66007 facility: Federal State Budgetary Institution "National Medical Research Center for Therapy and Preventive Medicine" of the Ministry of Health of the Russian Federation city: Moscow zip: 101990 country: Russian Federation lat: 55.75222 lon: 37.61556 facility: Federal Budgetary Institution of Science "Central Research Institute of Epidemiology" of the Federal Service for Supervision of Consumer Rights Protection and Human Well-being city: Moscow zip: 111123 country: Russian Federation lat: 55.75222 lon: 37.61556 facility: Unimed-S Zao city: Moscow zip: 119571 country: Russian Federation lat: 55.75222 lon: 37.61556 facility: I.M. Sechenov First Moscow State Medical University city: Moscow zip: 119991 country: Russian Federation lat: 55.75222 lon: 37.61556 facility: ErSi Medical LLC city: Novosibirsk zip: 630005 country: Russian Federation lat: 55.0415 lon: 82.9346 facility: Professorial Clinic LLC city: Perm zip: 614070 country: Russian Federation lat: 58.01046 lon: 56.25017 facility: Energia Zdoroviya LLC city: Saint Petersburg zip: 194156 country: Russian Federation lat: 59.93863 lon: 30.31413 facility: Medical Center Reavita Med SPb LLC city: Saint Petersburg zip: 194354 country: Russian Federation lat: 59.93863 lon: 30.31413 facility: Reavita Med SPb Medical Center LLC city: Saint Petersburg zip: 194354 country: Russian Federation lat: 59.93863 lon: 30.31413 facility: St. Petersburg State Budgetary Healthcare Institution "City Consultative and Diagnostic Center No. 1". city: Saint Petersburg zip: 194354 country: Russian Federation lat: 59.93863 lon: 30.31413 facility: Eco-Safety Research Center LLC city: Saint Petersburg zip: 196143 country: Russian Federation lat: 59.93863 lon: 30.31413 facility: Federal State Budgetary Institution "Consultative and Diagnostic Center with Polyclinic" of the Office of the President of the Russian Federation city: Saint Petersburg zip: 197110 country: Russian Federation lat: 59.93863 lon: 30.31413 facility: St. Petersburg State Budgetary Healthcare Institution "Consultative and Diagnostic Center No.85" city: Saint Petersburg zip: 198260 country: Russian Federation lat: 59.93863 lon: 30.31413 facility: Astarta LLC city: Saint Petersburg zip: 199226 country: Russian Federation lat: 59.93863 lon: 30.31413 facility: Federal State Budgetary Educational Institution of Higher Education "Saratov State Medical University named after V.I. Razumovsky" of the Ministry of Health of the Russian Federation city: Saratov zip: 410012 country: Russian Federation lat: 51.54056 lon: 46.00861 facility: Regional State budgetary healthcare institution "Clinical Hospital No. 1" city: Smolensk zip: 214006 country: Russian Federation lat: 54.7818 lon: 32.0401 facility: Federal State Budgetary Educational Institution of Higher Education "Siberian State Medical University" of the Ministry of Health of the Russian Federation city: Tomsk zip: 634050 country: Russian Federation lat: 56.49771 lon: 84.97437 facility: Budgetary healthcare institution of the Voronezh region "Voronezh Regional Clinical Hospital No. 1" city: Voronezh zip: 394066 country: Russian Federation lat: 51.67204 lon: 39.1843 facility: Medical Center for Diagnosis and Prevention plus LLC city: Yaroslavl zip: 150040 country: Russian Federation lat: 57.62987 lon: 39.87368 facility: The State Autonomous Healthcare Institution of the Yaroslavl region "Clinical Hospital No. 9" city: Yaroslavl zip: 150042 country: Russian Federation lat: 57.62987 lon: 39.87368 hasResults: False |
<|newrecord|> nctId: NCT06383806 id: STU00219933 id: 315-SR-23 type: OTHER_GRANT domain: American Academy of Sleep Medicine Foundation briefTitle: Decreasing Nightmares in Adults With Narcolepsy acronym: DAWN overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2026-09 date: 2026-09 date: 2024-04-25 date: 2024-04-25 name: Northwestern University class: OTHER briefSummary: The purpose of this clinical trial is learn whether a behavioral (non-medication) treatment can reduce nightmares in adults with narcolepsy. All participants will receive the treatment and will complete three assessments. Half of the participants will receive the treatment after the first assessment, and half will receive it after the second assessment. conditions: Narcolepsy conditions: Narcolepsy Type 1 conditions: Narcolepsy With Cataplexy conditions: Narcolepsy Without Cataplexy conditions: Nightmare conditions: Nightmare Disorder With Associated Other Sleep Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Waitlist control primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Imagery Rehearsal Therapy (IRT) measure: Disturbing Dream and Nightmare Severity Index (DDNSI) measure: Nightmare frequency (sleep diary) measure: PROMIS Anxiety measure: PROMIS Depression sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06383793 id: Northjiangsu000 briefTitle: Comparative Analysis of Short-Term Therapeutic Effects Between the π-Shaped and Overlap Methods for Esophagogastrostomy in Totally Laparoscopic Total Gastrectomy overallStatus: RECRUITING date: 2024-04-01 date: 2024-08-30 date: 2025-12-30 date: 2024-04-25 date: 2024-04-25 name: Northern Jiangsu People's Hospital class: OTHER briefSummary: As of now, although the safety of π-shaped anastomosis and the overlap method has been separately discussed in different contexts, there have been few studies considering a direct comparison of the results of these two methods. |
This article aims to explore the differences in the short-term therapeutic effects, surgical effectiveness, and safety between laparoscopic total gastrectomy with esophagogastrostomy using the overlap method and the π-shaped method. The goal is to provide new reference points for surgeons in the clinical decision-making process regarding the choice of anastomotic techniques during totally laparoscopic total gastrectomy. conditions: Gastric Cancer studyType: OBSERVATIONAL observationalModel: CASE_CROSSOVER timePerspective: RETROSPECTIVE count: 100 type: ESTIMATED name: overlap measure: 1 year survival sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Yifan Cheng status: RECRUITING city: Yangzhou state: Jiangsu zip: 225000 country: China name: Yifan Cheng role: CONTACT phone: 8615267258283 email: [email protected] lat: 32.39722 lon: 119.43583 hasResults: False |
<|newrecord|> nctId: NCT06383780 id: SYSKY-2023-901-01 briefTitle: Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis. overallStatus: RECRUITING date: 2024-05-01 date: 2027-05-01 date: 2027-05-01 date: 2024-04-25 date: 2024-04-25 name: XIANG YANQUN class: OTHER briefSummary: This is a prospective, open-label phase III clinical trial evaluating the efficacy and safety of the GP（Gemcitabine combined with cisplatin） regimen in combination with Tislelizumab versus the TPC（cisplatin, nab-paclitaxel and capecitabine）regimen in combination with Tislelizumab for the first-line treatment of Nasopharyngeal Carcinoma patients With Bone Metastasis. conditions: Nasopharyngeal Carcinoma studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Active Comparator:Drug:GP（Gemcitabine combined with cisplatin）regimen combined with Tislelizumab Experimental:Drug：TPC（cisplatin, nab-paclitaxel and capecitabine）regimen combined with Tislelizumab primaryPurpose: TREATMENT masking: NONE count: 90 type: ESTIMATED name: GP combined with Tislelizumab name: TPC combined with Tislelizumab measure: 1-year progression-free survival rate measure: Overall survival measure: incidence of adverse events measure: rate of skeletal-related events measure: Biomarker response (EBV-DNA, bone metabolic markers) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: SunYat-senU status: RECRUITING city: Guangzhou state: Guangdong zip: 510060 country: China name: Yanqun Xiang, MD role: CONTACT phone: +86-18666096623 email: [email protected] name: Weixiong Xia, MD role: CONTACT phone: +86-18520415699 email: [email protected] lat: 23.11667 lon: 113.25 hasResults: False |
<|newrecord|> nctId: NCT06383767 id: ESG401-301 briefTitle: A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer overallStatus: NOT_YET_RECRUITING date: 2024-06-30 date: 2026-07-31 date: 2026-12-31 date: 2024-04-25 date: 2024-04-25 name: Shanghai Escugen Biotechnology Co., Ltd class: INDUSTRY briefSummary: The aim of this study is to evaluate the efficacy and safety of ESG401 in patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer. conditions: Metastatic Breast Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 378 type: ESTIMATED name: ESG401 name: Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice) measure: Progression-free survival (PFS) assessed by IRC per RECIST 1.1 measure: Progression-free survival (PFS) assessed by the investigators per RECIST V 1.1 measure: Overall Survival (OS) measure: Objective Response Rate (ORR) measure: Clinical Benefit Rate (CBR) measure: Duration of Response (DoR) measure: Quality of life evaluated using the NCC-BC-A scale measure: Adverse events(AEs) and severe adverse events (SAEs) measure: Clearance measure: Volume of distribution measure: ADA sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cancer Hospital Chinese Academy of Medical Sciences city: Beijing state: Beijing zip: 100021 country: China name: Fei Ma, PhD role: CONTACT lat: 39.9075 lon: 116.39723 hasResults: False |
<|newrecord|> nctId: NCT06383754 id: Clove briefTitle: Clareon Intraocular Lens Stability in Vitrectomy Patients: CLOVE Study overallStatus: COMPLETED date: 2021-06-07 date: 2024-03-08 date: 2024-03-15 date: 2024-04-25 date: 2024-04-25 name: The University of Hong Kong class: OTHER briefSummary: This prospective randomized controlled trial will be conducted to investigate Clareon intraocular lens (IOL) stability in vitrectomy patients. The investigator plans to target the patients undergoing cataract surgery. A randomized study will be conducted with 2 arms, one with Clareon IOL versus a second arm using the Tecnis 1 In this non-inferiority study, the investigator will compare Clareon IOL from Alcon with the existing Tecnis 1 IOL from Precision Lens which is the commonly used intraocular lens in combined vitrectomy cases in Hong Kong. conditions: Senile Cataract conditions: Epiretinal Membrane conditions: Vitreous Hemorrhage studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Patients are randomised and masked from the treatment whoMasked: PARTICIPANT count: 50 type: ACTUAL name: Clareon name: Tecnis 1 measure: Position stability of Clareon and Tecnis 1 IOL measure: Visual acuity measure: Refraction measure: Axial movement measure: Decentration measure: Compare intra operative and post operative complication sex: ALL minimumAge: 50 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Grantham Hospital city: Hong Kong country: Hong Kong lat: 22.27832 lon: 114.17469 hasResults: False |
<|newrecord|> nctId: NCT06383741 id: 2023-00541 briefTitle: Predicting Outcomes in ICH Patients on Direct Factor Xa Inhibitors acronym: FIRE-Xa overallStatus: RECRUITING date: 2023-07-10 date: 2026-04-01 date: 2026-04-01 date: 2024-04-25 date: 2024-04-25 name: Insel Gruppe AG, University Hospital Bern class: OTHER briefSummary: This study focuses on direct factor Xa inhibitors (apixaban, edoxaban, rivaroxaban) and the thrombin inhibitor dabigatran, commonly used for stroke prevention in atrial fibrillation. Despite lower intracranial bleeding risks with these drugs, around 0.2-1.0% of patients annually experience intracranial hemorrhage (ICH), predominantly intracerebral. |
Treatment options for factor-Xa inhibitor-associated ICH, such as prothrombin complex concentrate (PCC) and andexanet alfa, lack direct comparison evidence except for ongoing trials like ANNEXA-I. This trial assesses hemostatic efficacy and 30-day functional outcomes but leaves gaps regarding anticoagulant activity's role and long-term effects, especially in patients presenting late after drug intake. |
The measurement of anti-FXa levels helps guide decisions, yet their link to hematoma expansion remains unknown. Efforts to streamline measurement within 30 minutes for acute decisions have shown variability in levels, with some patients exhibiting high levels even beyond 12 hours post-intake. This lack of data poses challenges, particularly for patients potentially benefiting from treatment beyond the current strict time window. |
Early hematoma expansion strongly predicts poor outcomes, but preventing it faces challenges like recurrent events (up to 5% by 3 months) and rehabilitation intensity, potentially negating its benefits. The ANNEXA-I trial evaluates short-term outcomes, highlighting the need for additional data to comprehend long-term ICH prognosis. |
The study's objectives involve linking hematoma expansion to anti-FXa levels, determining late-presenting patients' risk of expansion, and identifying predictors of favorable outcomes at 3, 6, and 12 months. Primary endpoints include functional outcomes, while secondary ones encompass expansion rates, anticoagulant activity, and various events at 12 months. |
This research aims to bridge gaps in understanding factor-Xa inhibitor-related ICH, addressing both immediate and prolonged outcomes to enhance clinical decision-making. conditions: Intra Cerebral Hemorrhage studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200 type: ESTIMATED measure: Good functional outcome measure: Good functional outcome measure: Good functional outcome measure: Haematoma expansion measure: Number of patients with significant anticoagulant activity arriving late measure: Absolute haematoma expansion (in ml) between baseline and follow-up imaging measure: Symptomatic haematoma expansion measure: Resumption of anticoagulant therapy after haemorrhage measure: Patients living at home measure: Functionally independent patients (mRS 0-2) measure: Excellent outcome (mRS 0-1) measure: Arterial and venous events at 12 months sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Insel Gruppe AG, Inselspital Bern status: RECRUITING city: Bern zip: 3010 country: Switzerland name: David J. Seiffge, Prof. Dr. med. role: CONTACT phone: +41 31 664 05 09 email: [email protected] name: Janis P. Rauch, PD Dr. med. role: CONTACT email: [email protected] lat: 46.94809 lon: 7.44744 hasResults: False |
<|newrecord|> nctId: NCT06383728 id: ES-2024-014-02 briefTitle: Osimertinib as Neoadjuvant Therapy in Patients With Resectable Stage II-IIIB EGFR-mutated Lung Squamous Cell Carcinoma acronym: GALAXY-02 overallStatus: RECRUITING date: 2024-04-01 date: 2025-10-31 date: 2029-04-30 date: 2024-04-25 date: 2024-04-25 name: The First Affiliated Hospital of Guangzhou Medical University class: OTHER briefSummary: Previous trials, such as ADURA and CTONG, have demonstrated the benefits of neoadjuvant targeted therapy in patient with EGFR mutations , which can effectively reduce the extent of tumors and improve the survival outcomes. However, clinical trials of neoadjuvant targeted therapy in NSCLC have rarely enrolled patients with EGFR-mutated lung squamous cell carcinoma due to its rarity, which means that the safety and feasibility of neoadjuvant osimertinib in patients with resectable stage II-IIIB EGFR-mutated lung squamous cell carcinoma remains relatively unknown. conditions: Lung Cancer conditions: Carcinoma, Squamous Cell studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Patients with resectable stage II-IIIB EGFR-mutated lung squamous cell carcinoma receive osimertinib (80mg/d, ≥9 weeks) primaryPurpose: TREATMENT masking: NONE count: 51 type: ESTIMATED name: Osimertinib measure: Objective Response Rate, ORR measure: Safety: frequency of severe adverse events measure: Major pathologic response, MPR measure: R0 rate measure: Progression-free survival (PFS) measure: Overall survival (OS) measure: Disease control rate (DCR) measure: Duration of remission (DOR) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Guangzhou Medical University status: RECRUITING city: Guangzhou state: Guangdong zip: 510120 country: China name: Shuben Li, Doctor role: CONTACT email: [email protected] lat: 23.11667 lon: 113.25 hasResults: False |
<|newrecord|> nctId: NCT06383715 id: 2024-624 briefTitle: Congitive Behavioral Therapy Workshop for Content Moderators overallStatus: RECRUITING date: 2024-05-01 date: 2024-06-01 date: 2024-08-01 date: 2024-04-25 date: 2024-04-26 name: Universidad Europea de Valencia class: OTHER briefSummary: Professional content moderators play a critical role in preventing Internet users from being exposed to more sensitive content. However, recent literature has shown that this work places content moderators at increased risk for several psychological outcomes, including intrusive thoughts and vicarious stress trauma. This pilot study will assess the acceptability and feasibility of a brief (4-session) cognitive-behavioral workshop to reduce these risks. conditions: Work-Related Condition conditions: Work-Related Stress Disorder studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: Cognitive-Behavioral Therapy Workshop for Content Moderators measure: The Kessler Psychological Distress Scale (K10) measure: Work Satisfaction Scale, JobStat'73 measure: Coping Mechanisms Scale measure: PTSD Checklist-Civilian Version (PCL-C) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MEGA cloud services status: RECRUITING city: Salamanca zip: 37002 country: Spain name: Valentina Sirna role: CONTACT phone: +34 685 34 79 07 email: [email protected] name: Carlos López-Pinar, PhD role: PRINCIPAL_INVESTIGATOR lat: 40.96882 lon: -5.66388 hasResults: False |
<|newrecord|> nctId: NCT06383702 id: HEX1939-002 briefTitle: Phase III Trial to Evaluate the Efficacy and Safety of Pregabalin in the Treatment of Painful Diabetic Peripheral Neuropathy overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2025-04-01 date: 2025-04-15 date: 2024-04-25 date: 2024-04-25 name: CSPC Ouyi Pharmaceutical Co., Ltd. class: INDUSTRY briefSummary: This study is designed to evaluate the efficacy and safety of pregabalin extended-release tablets in the treatment of neuropathic pain associated with diabetic peripheral neuropathy. Pregabalin has been approved in more than 130 countries for neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, and neuralgia associated with spinal cord injury. Pregabalin extended-release tablets were administered once daily, as a single dose after dinner. Compared with pregabalin capsule formulation, it reduces the frequency of medication and improves patient compliance. conditions: Neuropathic Pain Associated With Diabetic Peripheral Neuropathy studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel design primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 358 type: ESTIMATED name: pregabalin sustained-release tablets name: Placebo measure: NRS mean change at week 13 measure: NRS mean change at Weeks 1-12 and 14 measure: Proportion of subjects with NRS reduction measure: MOS-SS score measure: HADS score measure: PGIC score measure: CGIC score sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06383689 id: Az. 297/23-EP briefTitle: Placebo Optimization of the Presurgical Long-term Video-EEG Monitoring acronym: OPERA overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-04-30 date: 2026-12-31 date: 2024-04-25 date: 2024-04-25 name: University Hospital, Bonn class: OTHER briefSummary: The notion of genuine placebo effects on epileptic seizure events (i.e., effects beyond methodological study artifacts) is incompatible with the standard model of epilepsy seizure genesis. In this single-blind controlled study, the effectiveness of a covered placebo on (1) the timing of the occurrence of a first epileptic seizure ("seizure pill") versus (2) the subjective well-being ("comfort pill") during pre-surgical video-EEG monitoring will be examined. It is hypothesized that a placebo effect on subjective well-being can be demonstrated, but that epileptic seizure events are not influenced by placebo. conditions: Symptomatic Epilepsy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: monocentric single-blinded randomized clinical study on the effectiveness of covered placebo on epileptic seizure occurrence and emotional well-being with 3 study conditions: "seizure pill" (PCB-S), "well-being pill" (PCB-W) and no pill (control) primaryPurpose: BASIC_SCIENCE masking: SINGLE maskingDescription: Like in psychological studies, only patients can participate in the study who consent to accept that complete study information can only be provided after the entire study was finished (with an option to withdraw consent at that point) as information on ingredients of the study pill (which is placebo) must be concealed for inherent reasons (study on effects of covered placebo). whoMasked: PARTICIPANT count: 90 type: ESTIMATED name: Seizure placebo pill name: Well-being placebo pill measure: Latency to first epileptic seizure measure: Occurrence of an epileptic seizure measure: Early occurrence of an epileptic seizure within the first 72 hours measure: Number of epileptic seizures during the video-EEG measure: Number of early occurring epileptic seizures measure: Daily average frequency of epileptic seizures measure: Very early first epileptic seizure measure: Early epileptic seizure measure: Epileptic seizure within the first three days measure: Emotional well-being measure: Dissociative non-epileptic seizures sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Epileptology, University Hospital Bonn city: Bonn state: NRW zip: 53127 country: Germany name: Rainer Surges, Prof. role: CONTACT phone: +49 228 287-15727 email: [email protected] name: Christian Hoppe, PD Dr. role: CONTACT phone: +49 228 287-16172 email: [email protected] lat: 50.73438 lon: 7.09549 hasResults: False |
<|newrecord|> nctId: NCT06383676 id: 1 briefTitle: Effect Of Functional Balance Exercise İn Elderly acronym: RCT overallStatus: ACTIVE_NOT_RECRUITING date: 2023-04-20 date: 2024-11-30 date: 2025-05-30 date: 2024-04-25 date: 2024-04-25 name: Tarsus University class: OTHER briefSummary: The elderly population is increasing in Turkey and in the world. Many health problems, such as a decrease in physical and psychological abilities and an increase in chronic problems, occur with aging. It is important to encourage and support practices for the development of exercises to increase physical and cognitive capacity in order to early recognize and reduce the effects of problems that develop with aging. To the best of our knowledge, there is no exercise training to increase reaction time in the elderly in the literature. conditions: Older People conditions: Exercise studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The study was planned as a randomized controlled study primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Study participants are unaware of their assigned group whoMasked: PARTICIPANT count: 28 type: ACTUAL name: Functional reaction balance training name: Functional balance training measure: The Montreal Cognitive Assessment (MoCA) measure: Stroop Test measure: The Simple Reaction Time measure: The Four Square Step Test (FSST) measure: The short physical performance battery (SPPB) measure: Timed Up and Go Test (TUG) measure: Falls Efficacy Scale ( FES) measure: Mini-BESTest: Balance Evaluation Systems Test sex: ALL minimumAge: 65 Years maximumAge: 85 Years stdAges: OLDER_ADULT facility: Fatma Kübra ÇEKOK city: Ankara zip: 06000 country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False |
<|newrecord|> nctId: NCT06383663 id: 308-2019-04-01 briefTitle: A RCT of Supraclavicular Lymph Node Dissection vs. No-dissection in Supraclavicular Lymph Node Metastatic Breast Cancer overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2028-12-31 date: 2029-12-31 date: 2024-04-25 date: 2024-04-25 name: Sun Yat-sen University class: OTHER briefSummary: The purpose of this study was to compare the efficacy of surgical dissection of supraclavicular lymph nodes combined with radiotherapy versus radiotherapy alone in patients with ipsilateral supraclavicular lymph node metastasis. conditions: Breast Cancer conditions: Ipsilateral Supraclavicular Lymph Node Metastasis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Supraclavicular lymph node dissection combined with radiotherapy versus radiotherapy alone primaryPurpose: TREATMENT masking: NONE count: 452 type: ESTIMATED name: Supraclavicular lymph node dissection combined with radiotherapy name: radiotherapy measure: DFS measure: PFS measure: OS measure: pCR rate sex: FEMALE minimumAge: 35 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06383650 id: 124532 briefTitle: Use of 81 vs 325mg of ASA in Treatment of BCVI overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-05 date: 2025-09 date: 2024-04-25 date: 2024-04-25 name: London Health Sciences Centre class: OTHER name: Western University briefSummary: Blunt cerebrovascular injury (BCVI), or injury to the carotid and vertebral arteries, occurs in 1-3% of blunt traumas, often as a result of injury to the head, neck, or chest. If unrecognized or untreated, BCVI can lead to stroke, which occurs in approximately 20% of untreated patients, potentially causing significant and sometimes permanent disability. Early diagnosis and treatment significantly reduce the risk of stroke. |
Currently, there is wide variation across centers and trauma care providers in treatment strategies for BCVI and the most recent guidelines are unable to make specific recommendations about the optimal agent and/or dose of treatment to reduce the risk of stroke after BCVI while minimizing bleeding complications in patients with multiple traumatic injuries. Recent systematic reviews and meta-analyses evaluating the most common treatment strategies for BCVI have shown similar stroke rates with the use of anticoagulants (usually heparin) vs. antiplatelets (usually aspirin/ASA), however, treatment with antiplatelets was associated with a lower risk of bleeding complications. The optimal dose of ASA for stroke prevention while minimizing bleeding complications is unknown, and more research is required to inform future care. |
This project will investigate two doses of antiplatelet therapy (81 mg daily vs. 325 mg daily aspirin) for BCVI treatment, and will look at the risk of stroke and bleeding complications with each strategy. The goal of the research is to determine whether a large-scale study looking at this question is feasible, which will ultimately help determine the best medical therapy for patients with BCVI. conditions: Carotid Artery Injuries conditions: Traumatic Injury conditions: Vertebral Artery Injury studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Acetylsalicylic Acid measure: Study feasibility measure: Incidence of stroke measure: Incidence of Bleeding Complications sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06383637 id: KAP-ABR-Interns briefTitle: Antibiotic Use and Resistance KAP Among Dental Interns overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2024-11-01 date: 2024-12-01 date: 2024-04-25 date: 2024-04-25 name: Cairo University class: OTHER briefSummary: The study is designed as a cross-sectional online-based questionnaire, and it will be distributed among dental interns. Assess the following among dental interns (1) The knowledge, attitude, and practices (KAP) towards antibiotics and antibiotic resistance; (2) The correlation between their KAP score and where they spend their internship year? (4) Development of the curriculum to provide sufficient training and information about antibiotics and antibiotic resistance. conditions: Antibiotic Side Effect conditions: Antibiotic Resistant Infection studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 343 type: ESTIMATED measure: Knowledge of dental interns regarding antibiotic use and resistance sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06383624 id: RC18-4-2023 briefTitle: Impact Of Maternal Spinal Anesthesia-Induced Hypotension At Scheduled Cesarean Delivery On Risk Development Of Transient Tachypnea Of Newborn And Fetal Acidosis overallStatus: COMPLETED date: 2023-04-01 date: 2024-03-01 date: 2024-03-31 date: 2024-04-25 date: 2024-04-25 name: Benha University class: OTHER briefSummary: We will evaluate the association between transient tachypnea of newborns and fetal acidosis development to the degree and duration of maternal hypotension and anesthesia to delivery time during spinal anesthesia at scheduled cesarean delivery. conditions: Transient Tachypnea of Newborn and Fetal Acidosis studyType: OBSERVATIONAL observationalModel: CASE_CROSSOVER timePerspective: PROSPECTIVE count: 115 type: ACTUAL measure: Association between transient tachypnea of newborns development to the degree and duration of maternal hypotension during spinal anesthesia at scheduled cesarean delivery measure: Association between fetal acidosis development to the degree and duration of maternal hypotension and anesthesia to delivery time during spinal anesthesia at scheduled cesarean delivery sex: ALL minimumAge: 1 Minute maximumAge: 6 Hours stdAges: CHILD facility: Benha University Hospital city: Cairo zip: 13511 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False |
<|newrecord|> nctId: NCT06383611 id: OTX-0303 briefTitle: Expanded Access to Cyclic Irrigation in Patients Undergoing Exchange Arthroplasty acronym: APEX-EAP overallStatus: AVAILABLE date: 2024-04-25 date: 2024-04-25 name: Osteal Therapeutics, Inc. class: INDUSTRY briefSummary: The objective of the protocol is to provide access to the VT-X7 (Vancomycin, Tobramycin Exchanged in 7 Days) system for subjects with periprosthetic joint infection (PJI) of the hip or knee who lack therapeutic treatment alternatives. conditions: Prosthetic-joint Infection studyType: EXPANDED_ACCESS name: VT-X7 Treatment System sex: ALL minimumAge: 22 Years maximumAge: 84 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06383598 id: 2022KT74-ZY01 briefTitle: PD-L1 Specific [68Ga]-Nb-1 Nanobody Probe for PET Imaging in Solid Tumors overallStatus: RECRUITING date: 2024-05-09 date: 2026-12 date: 2026-12 date: 2024-04-25 date: 2024-04-25 name: Peking University Cancer Hospital & Institute class: OTHER briefSummary: The objective of the study is to constrcut a noninvasive approach 68Ga-Nb-1 PET/CT to detect the PD-L1 expression of tumor lesions in patients with solid tumors and to identify patients benefiting from anti-PD-L1 treatment. conditions: Solid Tumor studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 50 type: ESTIMATED name: 18F-FDG measure: Standardized uptake value（SUV） sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Cancer Hospital status: RECRUITING city: Beijing state: Beijing zip: 100142 country: China name: Hua Zhu role: CONTACT phone: +861088196495 email: [email protected] lat: 39.9075 lon: 116.39723 hasResults: False |
<|newrecord|> nctId: NCT06383585 id: 24-001367 briefTitle: 3D DL Ozteo in the Detection of Osseous Changes in Patients With Inflammatory Arthritis overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-06 date: 2026-12 date: 2024-04-25 date: 2024-04-25 name: Mayo Clinic class: OTHER name: GE Healthcare briefSummary: This project intends to explore and validate the utility of new MRI pulse sequence, 3D DL oZTEo, in the detection of osseous erosions of the hand in patients with inflammatory arthritis. The detection of osseous structural changes, such as erosive disease, is routinely assessed in patients with rheumatic conditions such as rheumatoid arthritis, as it alters clinical management, and in some cases assists in diagnosis. Currently, this is most often assessed with radiography and conventional MRI. conditions: Inflammatory Arthritis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 25 type: ESTIMATED name: oZTEo measure: The binary (yes/no) presence of bony erosions as detected by hand MRI with and without the addition of the 3D DL oZTEo sequence. measure: The number of erosions (continuous) as detected by hand MRI with and without the addition of the 3D DL oZTEo sequence. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Rochester city: Rochester state: Minnesota zip: 55905 country: United States lat: 44.02163 lon: -92.4699 hasResults: False |
<|newrecord|> nctId: NCT06383572 id: 2024-0196 id: NCI-2024-03505 type: OTHER domain: NCI-CTRP Clinical Registry briefTitle: Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies overallStatus: NOT_YET_RECRUITING date: 2024-10-31 date: 2027-04-01 date: 2029-04-01 date: 2024-04-25 date: 2024-04-25 name: M.D. Anderson Cancer Center class: OTHER briefSummary: To find a recommended dose of PRAME-TCR-NK cells that can be given to patients with AML or MDS. conditions: Lymphodepleting Chemotherapy conditions: Myeloid Malignancies studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 54 type: ESTIMATED name: Cyclophosphamide name: Fludarabine phosphate name: Decitabine measure: Safety and adverse events (AEs) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MD Anderson Cancer Center city: Houston state: Texas zip: 77030 country: United States name: Jeremy Ramdial, MD role: CONTACT phone: 713-745-0146 email: [email protected] name: Jeremy Ramdial, MD role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False |
<|newrecord|> nctId: NCT06383559 id: TJMUCH-GI-GC07 briefTitle: Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients overallStatus: RECRUITING date: 2023-12-01 date: 2026-07-01 date: 2026-09-01 date: 2024-04-25 date: 2024-04-25 name: Tianjin Medical University Cancer Institute and Hospital class: OTHER briefSummary: This is a multi-center, prospective, open label phase 2 study evaluating the safety and efficacy of standard first-line chemotherapy XELOX regimen combined with Sintilimab (anti-PD-1 antibody) and Lenvatinib in the treatment of advanced AFP-positive gastric cancer. This study was conducted in the Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute and Hospital. Previous phase 1 dose escalation study (TJMUCH-GI-GC002) has demonstrated that such combinational pattern was well tolerated with promising efficacy. In this study, patients with AFP-positive and HER-2-negative advanced gastric cancer who had not received palliative systematic treatment in the past will be enrolled. Patients who met the inclusion criteria were treated with XELOX regimen combined with Sintilimab plus Lenvatinib every 3 weeks until disease progression or intolerable adverse reactions or death. The treatment regimen is XELOX chemotherapy (oxaliplatin 130mg/ m2, d1, capecitabine 850-1250 mg/m2, bid, d1-14, every 3 weeks) in combination with Sintilimab (\>=60kg, 200 mg; \<60kg, 3mg/kg; intravenous infusion, every 3 weeks) plus Lenvatinib (determined from previous phase 1 study, 16mg, orally once a day). Patients received regular and periodic reviews, with imaging evaluations every 6 weeks. Safety will be evaluated by AE and laboratory tests. conditions: Gastric Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 39 type: ESTIMATED name: Lenvatinib and Sintilimab measure: ORR measure: OS measure: PFS measure: AE sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tianjin Medical University Cancer Institute and Hospital status: RECRUITING city: Tianjin state: Tianjin country: China name: Ting Deng, MD role: CONTACT phone: 022-23340123 phoneExt: 1053 email: [email protected] name: Yi Ba, MD role: CONTACT phone: 022-23340123 phoneExt: 1053 email: [email protected] lat: 39.14222 lon: 117.17667 hasResults: False |
<|newrecord|> nctId: NCT06383546 id: XHEC-C-2024-053-1 briefTitle: Artificial Intelligence-enabled ECG Detection of Congenital Heart Disease in Children: a Novel Diagnostic Tool acronym: AI-ECG-CHD overallStatus: RECRUITING date: 2024-01-01 date: 2024-12-30 date: 2025-12-30 date: 2024-04-25 date: 2024-04-25 name: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine class: OTHER briefSummary: Congenital heart disease (CHD) is the most common congenital disease in children. The early detection, diagnosis and treatment of CHD in children is of great significance to improve the prognosis and reduce the mortality of children, but the current screening methods have limitations. Electrocardiogram (ECG), as an economical and rapid means of heart disease detection, has a very important value in the auxiliary diagnosis of CHD.Big data and deep learning technologies in artificial intelligence (AI) have shown great potential in the medical field. The advent of the big data era provides rich data resources for the in-depth study of CHD ECG signals in children. The development of deep learning technology, especially the breakthrough in the field of image recognition, provides a strong technical support for the intelligent analysis of electrocardiogram. The particularity of children electrocardiogram requires the development of a special algorithm model. At present, the research on the application of deep learning models to identify children's electrocardiograms is limited, and the training and verification from large data sets are lacking. Based on the Chinese Congenital Heart Disease Collaborative Research Network, this project aims to integrate data and deep learning technology to develop a set of intelligent electrocardiogram assisted diagnosis system (CHD-ECG AI system) suitable for children with CHD, so as to improve the early detection rate of CHD and improve the efficiency of congenital heart disease screening. conditions: Artificial Intelligence conditions: Electrocardiogram conditions: Deep Learning conditions: Congenital Heart Disease in Children conditions: Diagnosis studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 30000 type: ESTIMATED measure: Large-scale ECG database for children measure: Artificial intelligence-assisted electrocardiogram model for CHD in Children sex: ALL minimumAge: 3 Months maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine status: RECRUITING city: Shanghai state: Shanghai country: China name: Sun Jing, MD role: CONTACT phone: 15618497517 email: [email protected] lat: 31.22222 lon: 121.45806 hasResults: False |
<|newrecord|> nctId: NCT06383533 id: IRB-2023-385 briefTitle: Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma overallStatus: RECRUITING date: 2023-05-01 date: 2025-05-01 date: 2025-12-31 date: 2024-04-25 date: 2024-04-26 name: Zhejiang Cancer Hospital class: OTHER briefSummary: It is a single arm, open-label, phase II cinical trial to evaluate the efficacy and safety of Disitamab Vedotin Plus Cadonilimab in second-line treatment of patients with Advanced or Metastatic Bile Duct Adenocarcinoma conditions: Bile Duct Adenocarcinoma Non-Resectable conditions: HER2 Gene Mutation studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 28 type: ESTIMATED name: Disitamab Vedotin Plus Cadonilimab measure: Objective response rate(ORR) measure: Overall survival (OS) measure: Progression-free survival (PFS) measure: Disease control rate (DCR) measure: Incidence of Treatment-Emergent 3/4 Adverse Events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Zhejiang Cancer Hospital status: RECRUITING city: Hangzhou state: Zhejiang zip: 310022 country: China name: Jieer Ying, Doctor role: CONTACT phone: 13858195803 email: [email protected] lat: 30.29365 lon: 120.16142 hasResults: False |
<|newrecord|> nctId: NCT06383520 id: XLan-0415 briefTitle: Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma overallStatus: RECRUITING date: 2023-09-30 date: 2024-12-30 date: 2025-12 date: 2024-04-25 date: 2024-04-25 name: Wuhan Union Hospital, China class: OTHER briefSummary: This is a diagnostic study. Patients were recruited from patients with clinically suspected or confirmed hepatocellular carcinoma and healthy volunteers were recruited for PET/or PET/CT imaging targeting a GPC3-specific probe (in the case of 68Ga-NOTA-aGPC3-scFv) , to observe the reaction of volunteers and patients after injection of drugs, to evaluate the pharmacokinetics in vivo and the efficacy of diagnosis and staging, and to perform PET CT imaging in patients with contraindications. General Information, clinical data, blood routine, liver and renal function, and other imaging data were collected. The final diagnosis was based on the histopathology of biopsy or surgical specimens. conditions: Malignant Neoplasm of Liver studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 100 type: ESTIMATED name: 68Ga-aGPC3-scFv/Fab measure: Visual and standardized uptake values assessment of lesions and biodistribution measure: Radioactivity in the blood and urine samples measure: Concentration of tumor markers (e.g., APF) in participants' blood measure: Pathological sections of tumour tissue sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: China, Hubei Province status: RECRUITING city: Wuhan state: Hubei zip: 430022 country: China name: Xiaoli Lan, PhD role: CONTACT phone: +86-027-83692633 email: [email protected] lat: 30.58333 lon: 114.26667 hasResults: False |
<|newrecord|> nctId: NCT06383507 id: CHT101 briefTitle: A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors overallStatus: NOT_YET_RECRUITING date: 2024-04-22 date: 2027-04-21 date: 2029-04-21 date: 2024-04-25 date: 2024-04-25 name: Zhejiang University class: OTHER briefSummary: This is a single-center, single-arm ，open-label ，dose escalation and dose extension study. In this study we plan to evaluate the safety and efficacy of CD70-targeting UCAR-T cells in the treatment of CD70-positive refractory or relapsed solid tumors, and obtain recommended doses and infusion patterns. conditions: Metastatic Tumor conditions: Advanced Solid Tumor conditions: Renal Cell Carcinoma conditions: Ovarian Cancer conditions: Cervix Cancer conditions: Head and Neck Squamous Cell Carcinoma conditions: Nasopharyngeal Carcinoma studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 18 type: ESTIMATED name: CHT101 measure: Incidence of Adverse events after CD70 UCAR-T cells infusion (Safety and Tolerability) measure: Disease control rate (DCR) measure: Objective response rate (ORR) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06383494 id: IRB-2024-356（IIT） briefTitle: GMA-TulipTM, i-gelTM and the LMA-SupremeTM (LMA-S) Devices in Airway Management overallStatus: RECRUITING date: 2024-04-30 date: 2025-12-30 date: 2025-12-30 date: 2024-04-25 date: 2024-04-26 name: Zhejiang Cancer Hospital class: OTHER briefSummary: Patients were randomly assigned to three extraglottic airway (EGA) devices groups for airway management after anesthesia induced. Fiberoptic bronchoscope (FB) guided glottic exposure grading was performed and other airway management quality was recorded. conditions: Anesthesia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: FACTORIAL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 276 type: ESTIMATED name: LMA supreme group name: I-gel group name: GMA-Tulip measure: Glottic exposure grading measure: Peak inspiratory pressures measure: Pharyngalgia measure: Bleeding sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Zhejiang Cancer Hospital status: RECRUITING city: Hangzhou state: Zhejiang zip: 310022 country: China name: Jiangling Wang, Ph. D role: CONTACT phone: +86 571 88122106 email: [email protected] lat: 30.29365 lon: 120.16142 hasResults: False |
<|newrecord|> nctId: NCT06383481 id: TDK-2024-13362 briefTitle: The Effect of Mobile-Based Education on Postoperative Recovery and Quality of Life in Thyroidectomy Patients overallStatus: NOT_YET_RECRUITING date: 2024-04-22 date: 2025-04-22 date: 2025-08-22 date: 2024-04-25 date: 2024-04-26 name: Ataturk University class: OTHER briefSummary: Thyroid diseases constitute one of the most common health problems around the world and in our country. In its treatment; Drug therapy, radioactive iodine therapy and surgical treatment can be applied alone or together. Advances in the diagnosis of thyroid diseases have led to an increase in the number of thyroidectomies. When there are no complications after thyroidectomy, patients are discharged from the hospital on the day of surgery or are hospitalized for only a few days. In this context, since technical care is given priority, discharge training remains incomplete. |
Patients who have had thyroidectomy are discharged within 1-2 days after surgery if no problems occur. For this reason, patient education provided by health professionals and especially nurses may be insufficient. Post-discharge patient education in surgical services can sometimes be ignored, and it is noteworthy that this situation is not given importance due to the busy nature of surgical services. Although short hospital stays after surgery are beneficial in many ways, it increases the need for patient education. |
In this study, a mobile application that covers the entire perioperative process and includes education will be developed for patients undergoing thyroidectomy. This developed mobile application aims to manage post-operative problems such as neck pain and discomfort and voice changes experienced by patients, and to improve post-operative recovery, voice quality and, accordingly, quality of life. In this context, it is believed that even in cases where patients cannot access health care professionals, their educational needs will be met, problem management will be provided with applications for the problems they experience, and accordingly, their post-operative recovery, voice and quality of life will increase, starting from the hospital before the surgery until the end of the recovery period, including the home care process after discharge.When the literature on the subject is examined, studies involving education in patients with thyroidectomy are limited. However, no studies have been found on mobile health applications that include training to reduce neck pain and discomfort experienced by thyroidectomy patients, ensure postoperative recovery, and improve voice quality and quality of life. conditions: Thyroid Diseases conditions: Healthy Lifestyle conditions: Thyroid studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 92 type: ESTIMATED name: Mobile based education measure: Postoperative Recovery Index (ASII) measure: SF-36 Quality of Life Scale measure: Visual Comparison Pain Scale(GKAÖ) measure: Turkish- Computer System Usability Questionnaire Short Version (TCSUQ- SV) measure: Neck Pain and Discomfort Scale (BARÖ) measure: Voice Handicap Index (Voice Handicap Index 10)(VHI10) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06383468 id: AK120-301 briefTitle: A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis overallStatus: RECRUITING date: 2024-04-30 date: 2025-01-30 date: 2026-01-30 date: 2024-04-25 date: 2024-04-25 name: Akeso class: INDUSTRY briefSummary: This is a randomized double-blind, placebo-controlled, multicenter phase III clinical study evaluating the efficacy and safety of AK120 injection in the treatment of patients with moderate to severe atopic dermatitis. conditions: Atopic Dermatitis studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 420 type: ESTIMATED name: AK120 measure: Percentage of subjects who achieved (Eczema Area and Severity Index) EASI-75 measure: Percentage of subjects who achieved 0/1 in the (Investigator's Global Assessment) IGA sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Friendship Hospital Capital Medical University status: RECRUITING city: Beijing state: Beijing country: China lat: 39.9075 lon: 116.39723 facility: Beijing Luhe Hospital Affiliated to Capital Medical University status: RECRUITING city: Beijing state: Beijing country: China lat: 39.9075 lon: 116.39723 facility: Beijing Tongren Hospital status: RECRUITING city: Beijing state: Beijing country: China lat: 39.9075 lon: 116.39723 facility: Peking University People's Hospital status: RECRUITING city: Beijing state: Beijing country: China lat: 39.9075 lon: 116.39723 facility: Peking University Third Hospital status: RECRUITING city: Beijing state: Beijing country: China lat: 39.9075 lon: 116.39723 facility: Chongqing Three Gorges Medical College Affiliated People's Hospital status: RECRUITING city: Chongqing state: Chongqing country: China lat: 29.56278 lon: 106.55278 facility: Chongqing Traditional Chinese Medicine Hospital status: RECRUITING city: Chongqing state: Chongqing country: China lat: 29.56278 lon: 106.55278 facility: The First Affiliated Hospital of Fujian Medical University status: RECRUITING city: Fuzhou state: Fujian country: China lat: 26.06139 lon: 119.30611 facility: The Second Affiliated Hospital of Xiamen Medical College status: RECRUITING city: Xiamen state: Fujian country: China lat: 24.47979 lon: 118.08187 facility: Guangdong Provincial People's Hospital status: RECRUITING city: Guangzhou state: Guangdong country: China lat: 23.11667 lon: 113.25 facility: Southern Medical University Dermatology Hospital/Guangdong Provincial Dermatology Hospital status: RECRUITING city: Guangzhou state: Guangdong country: China lat: 23.11667 lon: 113.25 facility: Southern Medical University Southern Hospital status: RECRUITING city: Guangzhou state: Guangdong country: China lat: 23.11667 lon: 113.25 facility: Sun Yat-sen Memorial Hospital, Sun Yat-sen University status: RECRUITING city: Guangzhou state: Guangdong country: China lat: 23.11667 lon: 113.25 facility: The First Affiliated Hospital of Guangzhou Medical University status: RECRUITING city: Guangzhou state: Guangdong country: China lat: 23.11667 lon: 113.25 facility: Zhujiang Hospital of Southern Medical University status: RECRUITING city: Guangzhou state: Guangdong country: China lat: 23.11667 lon: 113.25 facility: Yuebei People's hospital, Guangdong, China status: RECRUITING city: Shaoguan state: Guangdong country: China lat: 24.8 lon: 113.58333 facility: Shunde Hospital of Southern Medical University status: RECRUITING city: Shunde state: Guangdong country: China lat: 22.84067 lon: 113.2503 facility: Guangdong Medical University Affiliated Hospital status: RECRUITING city: Zhanjiang state: Guangdong country: China lat: 21.28145 lon: 110.34271 facility: The Affiliated Hospital of Guizhou Medical University status: RECRUITING city: Guiyang state: Guizhou country: China lat: 26.58333 lon: 106.71667 facility: Hainan General Hospital status: RECRUITING city: Haikou state: Hainan country: China lat: 20.04583 lon: 110.34167 facility: Hainan Provincial Fifth People's Hospital status: RECRUITING city: Haikou state: Hainan country: China lat: 20.04583 lon: 110.34167 facility: The First Affiliated Hospital of Hainan Medical College status: RECRUITING city: Haikou state: Hainan country: China lat: 20.04583 lon: 110.34167 facility: Chengde Medical College Affiliated Hospital status: RECRUITING city: Chengde state: Hebei country: China lat: 40.9519 lon: 117.95883 facility: The Second Affiliated Hospital of Xingtai Medical College status: RECRUITING city: Xingtai state: Hebei country: China lat: 37.06306 lon: 114.49417 facility: Harbin Medical University Affiliated Second Hospital status: RECRUITING city: Harbin state: Heilongjiang country: China lat: 45.75 lon: 126.65 facility: Heilongjiang Provincial Hospital status: RECRUITING city: Harbin state: Heilongjiang country: China lat: 45.75 lon: 126.65 facility: The Second Affiliated Hospital of Henan University of Science and Technology status: RECRUITING city: Luoyang state: Henan country: China lat: 34.68361 lon: 112.45361 facility: Renmin Hospital of Wuhan University Hubei General Hospital status: RECRUITING city: Wuhan state: Hubei country: China lat: 30.58333 lon: 114.26667 facility: Tongji Hospital status: RECRUITING city: Wuhan state: Hubei country: China lat: 30.58333 lon: 114.26667 facility: Changde First People's Hospital status: RECRUITING city: Changde state: Hunan country: China lat: 29.04638 lon: 111.6783 facility: Xiangya Hospital of Central South University status: RECRUITING city: Changsha state: Hunan country: China lat: 28.19874 lon: 112.97087 facility: The First Affiliated Hospital of South China University status: RECRUITING city: Hengyang state: Hunan country: China lat: 26.88946 lon: 112.61888 facility: Inner Mongolia Medical University Affiliated Hospital status: RECRUITING city: Hohhot state: Inner Mongolia country: China lat: 40.81056 lon: 111.65222 facility: The First Affiliated Hospital of Bengbu Medical College status: RECRUITING city: Bengbu state: Jiangsu country: China lat: 32.94083 lon: 117.36083 facility: Changzhou First People's Hospital status: RECRUITING city: Changzhou state: Jiangsu country: China lat: 31.77359 lon: 119.95401 facility: Yancheng First People's Hospital status: RECRUITING city: Yancheng state: Jiangsu country: China lat: 33.3575 lon: 120.1573 facility: Jiangsu University Affiliated Hospital status: RECRUITING city: Zhenjiang state: Jiangsu country: China lat: 32.21086 lon: 119.45508 facility: The First Affiliated Hospital of Gannan Medical College status: RECRUITING city: Ganzhou state: Jiangxi country: China facility: The First Bethune Hospital of Jilin University status: RECRUITING city: Changchun state: Jilin country: China lat: 43.88 lon: 125.32278 facility: Panjin Liaoyou Gemstone Flower Hospital status: RECRUITING city: Panjin state: Liaoning country: China lat: 41.121 lon: 122.0739 facility: Shenyang Integrated Traditional Chinese and Western Medicine Hospital status: RECRUITING city: Shenyang state: Liaoning country: China lat: 41.79222 lon: 123.43278 facility: Zhongyi Northeast International Hospital status: RECRUITING city: Shenyang state: Liaoning country: China lat: 41.79222 lon: 123.43278 facility: General Hospital of Ningxia Medical University status: RECRUITING city: Yinchuan state: Ningxia country: China lat: 38.46806 lon: 106.27306 facility: Shandong Provincial Dermatology Hospital status: RECRUITING city: Jinan state: Shandong country: China lat: 36.66833 lon: 116.99722 facility: Shandong University Qilu Hospital status: RECRUITING city: Jinan state: Shandong country: China lat: 36.66833 lon: 116.99722 facility: Qingdao Municipal Hospital status: RECRUITING city: Qingdao state: Shandong country: China lat: 36.06488 lon: 120.38042 facility: Shanghai Dermatology Hospital status: RECRUITING city: Shanghai state: Shanghai country: China lat: 31.22222 lon: 121.45806 facility: Baoji Central Hospital status: RECRUITING city: Baoji state: Shanxi country: China facility: Sichuan Provincial People's Hospital status: RECRUITING city: Chengdu state: Sichuan country: China lat: 30.66667 lon: 104.06667 facility: Tianjin Institute of Traditional Chinese Medicine Affiliated Hospital status: RECRUITING city: Tianjin state: Tianjin country: China lat: 39.14222 lon: 117.17667 facility: Xinjiang Uygur Autonomous Region People's Hospital status: RECRUITING city: Urumqi state: Xinjiang country: China lat: 43.80096 lon: 87.60046 facility: The First Affiliated Hospital of Kunming Medical University status: RECRUITING city: Kunming state: Yunnan country: China lat: 25.03889 lon: 102.71833 facility: Hangzhou First People's Hospital status: RECRUITING city: Hangzhou state: Zhejiang country: China lat: 30.29365 lon: 120.16142 facility: Hangzhou Third People's Hospital status: RECRUITING city: Hangzhou state: Zhejiang country: China lat: 30.29365 lon: 120.16142 facility: The Second Affiliated Hospital of Zhejiang University School of Medicine status: RECRUITING city: Hangzhou state: Zhejiang country: China lat: 30.29365 lon: 120.16142 facility: Jiaxing First People's Hospital status: RECRUITING city: Jiaxing state: Zhejiang country: China lat: 30.7522 lon: 120.75 facility: Ningbo First Hospital status: RECRUITING city: Ningbo state: Zhejiang country: China lat: 29.87819 lon: 121.54945 facility: Ningbo Huamei Hospital, University of Chinese Academy of Sciences status: RECRUITING city: Ningbo state: Zhejiang country: China lat: 29.87819 lon: 121.54945 facility: Wenzhou Medical University First Affiliated Hospital status: RECRUITING city: Wenzhou state: Zhejiang country: China lat: 27.99942 lon: 120.66682 hasResults: False |
<|newrecord|> nctId: NCT06383455 id: Observational briefTitle: Effects of Smoking on Clinical and Microbiological Response in Individuals With Periodontitis overallStatus: COMPLETED date: 2018-09-15 date: 2019-02-01 date: 2019-03-01 date: 2024-04-25 date: 2024-04-25 name: Trakya University class: OTHER briefSummary: This study aimed to compare the distribution of subgingival periodontal pathogens following non-surgical periodontal therapy in smoking and non-smoking people with periodontitis. The main question it aims to answer is: |
- Does smoking affect the results of non-surgical periodontal treatment on subgingival flora in participants with periodontal disease? |
Researchers performed non-surgical periodontal therapy on 48 participants with stage III/IV periodontitis and recorded clinical measurements. They obtained subgingival plaque samples from periodontal pockets at the onset and after four weeks of treatment, determining the level of periodontopathogens using a polymerase chain reaction-based method. conditions: Periodontitis conditions: Smoking Habit conditions: Subgingival Plaque studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 48 type: ACTUAL name: Non-surgical periodontal therapy measure: Change in levels of periodontopathogens in subgingival plaque after non-surgical periodontal therapy in smokers and non-smokers with stage 3/4 periodontitis measure: Change in clinical attachment level (CAL) measure: Change in probing depth (PD) measure: Change in gingival index (GI) scores measure: Change in plaque index (PI) scores measure: Change in Bleeding on Probing (BOP) sex: ALL minimumAge: 35 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Trakya University city: Edirne zip: 22030 country: Turkey lat: 41.67719 lon: 26.55597 hasResults: False |
<|newrecord|> nctId: NCT06383442 id: N202103041 briefTitle: HIIT on Overweight Middle-aged Adults acronym: HIIT overallStatus: COMPLETED date: 2021-05-25 date: 2023-07-31 date: 2023-11-22 date: 2024-04-25 date: 2024-04-25 name: Taipei Medical University class: OTHER briefSummary: 36 middle-aged with overweight adults were divided into three groups: 1. L-HIIT group: the long-interval HIIT group (4 × 4 min Exercise/4 min Rest), 2. M-HIIT group: the medium-interval HIIT group (8 × 2 min Exercise/2 min Rest), 3. Control group: no exercise intervention. All groups carried out the training stage for 8 weeks (three sessions per week) and the detraining stage for 4 weeks in order to investigate the effects induced by different HIIT interventions on inflammation, metabolic adaptation, anti-fatigue and exercise performance, and fat loss. conditions: Overweight or Obesity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants were evenly distributed according to a counterbalanced design and divided into three different groups by the body fat percentage of subjects: 1. L-HIIT group: the long-interval HIIT group (4 × 4 min Exercise/4 min Rest), 2. M-HIIT group: the medium-interval HIIT group (8 × 2 min Exercise /2 min Rest), 3. Control group. Target intensities of each interval bout, exercise and rest (Ex./R.), were 85-90% VO2peak/65-70% VO2peak zones, respectively. primaryPurpose: OTHER masking: NONE count: 36 type: ACTUAL name: L-HIIT name: M-HIIT measure: Aerobic Capacity Test measure: Aerobic Capacity Test measure: Anti-fatigue performance measure: skinfold thickness measure: Body composition_body fat measure: Glucose measure: Triglycerides measure: low-density lipoprotein (LDL) measure: high-density lipoprotein (HDL) measure: creatine kinase (CK) level measure: C-reactive protein (CRP) measure: tumor necrosis factor (TNF)-R1 measure: TNF-R2 sex: ALL minimumAge: 20 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Taipei Medical University city: Taipei zip: 110 country: Taiwan lat: 25.04776 lon: 121.53185 hasResults: False |
<|newrecord|> nctId: NCT06383429 id: P.T-WH-10/2023-521 briefTitle: Relation Between Forward Head Posture and Incidence of Headache in Obese Adults overallStatus: COMPLETED date: 2024-01-01 date: 2024-03-14 date: 2024-04-15 date: 2024-04-25 date: 2024-04-25 name: Ahram Canadian University class: OTHER briefSummary: Cross sectional study to detect relation between forward head posture and headache. We will take information from the patient about: |
* Detailed history of patient |
* Forward head posture by using mobile application |
* Headache disability index conditions: Obese conditions: Headache conditions: Neck Pain studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 40 type: ACTUAL name: forward head posture by using mobile application. And patients will fill out headache disability index. measure: forward head posture measure: BMI measure: headache disability index sex: ALL minimumAge: 20 Years maximumAge: 30 Years stdAges: ADULT facility: Ababa physical therapy center city: Banī Suwayf state: Beni- Suaf zip: 2711860 country: Egypt lat: 29.07441 lon: 31.09785 hasResults: False |
<|newrecord|> nctId: NCT06383416 id: P.T-INT-10/2023-522 briefTitle: Incidence of Headache and Its Effect on Quality of Life in Geriatric Patients With Chronic Neck Pain overallStatus: COMPLETED date: 2024-01-21 date: 2024-03-20 date: 2024-04-20 date: 2024-04-25 date: 2024-04-25 name: Ahram Canadian University class: OTHER briefSummary: cross sectional study to detect the incidence of headache and its effect on quality of life in geriatric patients with chronic neck pain. Patients will fill out quality of life questionnaire and headache disability index. We will take information from the patients about: |
* The frequency of headache occurrence. |
* Visual analogue scale of chronic neck pain. Main measures: chronic neck pain will be assessed by visual analogue scale. Patients will fill out quality of life questionnaire and headache disability index. conditions: Geriatric Patients With Neck Pain studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 40 type: ACTUAL name: Neck pain by VAS measure: Visual analogue scale measure: headache disability index measure: SF-36 quality of life questionare sex: ALL minimumAge: 60 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ababa physical therapy center city: Banī Suwayf zip: 2711860 country: Egypt lat: 29.07441 lon: 31.09785 hasResults: False |
<|newrecord|> nctId: NCT06383403 id: CLIN-60190-463 id: 2024-510695-20-00 type: CTIS briefTitle: A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. acronym: ELSPIRE overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2026-06-22 date: 2026-12-21 date: 2024-04-25 date: 2024-04-25 name: Ipsen class: INDUSTRY briefSummary: The participants in this study will have confirmed PBC with inadequate response or intolerance to Ursodeoxycholic acid (UDCA), which is a medication used in the management and treatment of cholestatic liver disease. |
Primary biliary cholangitis is a slowly progressive disease characterised by damage of the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. |
Many patients with PBC may require a liver transplant or may die if the disease progresses and a liver transplant is not done. This study will compare a daily dose of elafibranor (the study drug) to a daily dose of placebo (a dummy treatment). |
The main aim of this study is to determine if elafibranor is better than placebo in reducing ALP levels to a normal value. High ALP levels in the blood can indicate liver disease. |
There will be three periods in this study: A screening period (up to 8 weeks) to assess whether the participant can take part; a treatment period (up to 52 weeks) where eligible participants will be grouped as per their blood ALP levels and randomly assigned to either receive elafibranor or placebo, and a follow-up period (4 weeks) where participants' health will be monitored. |
Participants will be twice as likely to receive elafibranor than placebo (2:1 ratio). |
Participants will undergo blood sampling, urine collections, physical examinations, clinical evaluations, electrocardiograms (ECG: recording of the electrical activity of heart), ultrasound examinations (a noninvasive test that passes a probe over skin to look at the bladder, urinary tract, and liver), and Fibroscan® examinations (a noninvasive test that passes a probe on skin to measure stiffness of the liver). |
They will also be asked to fill in questionnaires. Each participant will be in this study for up to 64 weeks (15 months). conditions: Primary Biliary Cholangitis studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 72 type: ESTIMATED name: Elafibranor name: Placebo measure: Percentage of participants with normalisation of Alkaline Phosphate (ALP) Levels measure: Percentage of participants with normalisation of ALP Levels measure: Change from baseline in ALP levels measure: Percentage of participants with normalisation of ALP Levels and ≥15% decrease from Baseline measure: Percentage of participants with ≥40% decrease from Baseline in ALP Levels measure: Percentage of participants with ALP <0.5 × Upper Limit of Normal (ULN) measure: Changes from baseline in Total Bilirubin (TB) Levels measure: Percentage of participants with TB <0.7 × ULN measure: Percentage of participants with normalisation of ALP and TB <0.7 × ULN measure: Percentage of participants with normalisation of TB and ALP Levels measure: Percentage of participants with complete biochemical response measure: Change from baseline in PBC Worst Itch Numeric Rating Scale (NRS) score measure: Percentage of participants with moderate to severe pruritus at baseline (i.e. score ≥4) with a clinically meaningful response in PBC Worst Itch NRS measure: Change from baseline in 5-D itch score measure: Change from baseline in Patient Global Impression of Severity (PGI-S) scores measure: Patient Global Impression of Change (PGI-C) scores measure: Change from baseline in PBC-40 Quality of Life (QoL) scores measure: Change from baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 7a scores measure: Percentage of participants experiencing Treatment- Emergent Adverse Events (TEAEs), treatment- related TEAEs, Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs). measure: Percentage of participants developing clinically significant changes in physical examination measure: Percentage of participants developing clinically significant changes in vital signs measure: Percentage of participants developing clinically significant changes in Electrocardiogram (ECG) Readings measure: Percentage of participants developing clinically significant changes in laboratory parameters sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False |
<|newrecord|> nctId: NCT06383390 id: 18584 id: J1I-MC-GZBO type: OTHER domain: Eli Lilly and Company id: 2023-508630-34-00 type: OTHER domain: EU CTR Number briefTitle: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES) overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2029-02 date: 2029-02 date: 2024-04-25 date: 2024-04-25 name: Eli Lilly and Company class: INDUSTRY briefSummary: The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. conditions: Overweight and Obesity studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 10000 type: ESTIMATED name: Retatrutide name: Placebo measure: Time to First Occurrence of Composite Endpoints measure: Time to First Occurrence of Composite Endpoint of End Stage Kidney Disease (ESKD), ≥ 40% Sustained Decline in Estimated Glomerular Filtration Rate (eGFR), CV Death or Renal Death measure: Time to First Occurrence of Composite Endpoint of Major Cardiovascular Events (MACE-3) measure: Time to First Occurrence of Composite Endpoint of CV death, or hospitalization or urgent visit due to HF measure: Time to Occurrence of All-Cause Death measure: Time to First Occurrence of composite endpoint of ≥ 40% Sustained Decline in eGFR, End-Stage Renal Disease (ESRD), or Renal Death measure: Percentage change from Baseline in Albuminuria urinary albumin/creatinine ratio (UACR) in Participants with UACR ≥30 mg/g (0.03 mg/mg) at baseline sex: ALL minimumAge: 45 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Central Research Associates city: Birmingham state: Alabama zip: 35205 country: United States name: David D. DeAtkine role: PRINCIPAL_INVESTIGATOR lat: 33.52066 lon: -86.80249 facility: Alliance for Multispecialty Research, LLC city: Daphne state: Alabama zip: 36526 country: United States name: Michael T. Ledet role: PRINCIPAL_INVESTIGATOR lat: 30.60353 lon: -87.9036 facility: Nephrology Consultants city: Huntsville state: Alabama zip: 35805 country: United States name: Michael Quadrini role: PRINCIPAL_INVESTIGATOR lat: 34.7304 lon: -86.58594 facility: Alliance for Multispecialty Research, LLC city: Mobile state: Alabama zip: 36608 country: United States name: Harry E Studdard role: PRINCIPAL_INVESTIGATOR lat: 30.69436 lon: -88.04305 facility: Alaska Heart and Vascular Institute city: Anchorage state: Alaska zip: 99508 country: United States name: Suneet Nitin Purohit role: PRINCIPAL_INVESTIGATOR lat: 61.21806 lon: -149.90028 facility: Helios Clinical Research - SAZ-PDV-026 city: Paradise Valley state: Arizona zip: 85253 country: United States name: Gerald Asin role: PRINCIPAL_INVESTIGATOR lat: 33.53115 lon: -111.94265 facility: Phoenix Clinical LLC city: Phoenix state: Arizona zip: 85014 country: United States name: Brock Adam Merritt role: PRINCIPAL_INVESTIGATOR lat: 33.44838 lon: -112.07404 facility: Arizona Cardiovascular Research Center city: Phoenix state: Arizona zip: 85016 country: United States name: Vijendra Swarup role: PRINCIPAL_INVESTIGATOR lat: 33.44838 lon: -112.07404 facility: Synexus Clinical Research US, Inc./Orange Grove Family Practice city: Tucson state: Arizona zip: 85741 country: United States name: Kevin Lee Pounds role: PRINCIPAL_INVESTIGATOR lat: 32.22174 lon: -110.92648 facility: Cardiology and Medicine Clinic city: Little Rock state: Arkansas zip: 72204 country: United States name: Joe Louis Hargrove role: PRINCIPAL_INVESTIGATOR lat: 34.74648 lon: -92.28959 facility: Kidney & Hypertension Center - Apple Valley city: Apple Valley state: California zip: 92307 country: United States name: Edgard Vera role: PRINCIPAL_INVESTIGATOR lat: 34.50083 lon: -117.18588 facility: AHF Westside city: Beverly Hills state: California zip: 90211 country: United States name: Carl E Millner role: PRINCIPAL_INVESTIGATOR lat: 34.07362 lon: -118.40036 facility: Hope Clinical Research, Inc. city: Canoga Park state: California zip: 91303 country: United States name: Hessam Aazami role: PRINCIPAL_INVESTIGATOR lat: 34.20112 lon: -118.59814 facility: Valley Clinical Trials, Inc. city: Covina state: California zip: 91723 country: United States name: Fahed G Bitar role: PRINCIPAL_INVESTIGATOR lat: 34.09001 lon: -117.89034 facility: Neighborhood Healthcare Institute of Health city: Escondido state: California zip: 92025 country: United States name: James H Schultz role: PRINCIPAL_INVESTIGATOR lat: 33.11921 lon: -117.08642 facility: HB Clinical Trials - Fountain Valley city: Fountain Valley state: California zip: 92708 country: United States name: Vinod Malhotra role: PRINCIPAL_INVESTIGATOR lat: 33.70918 lon: -117.95367 facility: Scripps Whittier Diabetes Institute city: La Jolla state: California zip: 92037 country: United States name: Athena Philis-Tsimikas role: PRINCIPAL_INVESTIGATOR lat: 32.84727 lon: -117.2742 facility: North America Research Institute city: Lynwood state: California zip: 90262 country: United States name: Sita Yanamadala role: PRINCIPAL_INVESTIGATOR lat: 33.93029 lon: -118.21146 facility: Valley Clinical Trials, Inc. city: Northridge state: California zip: 91325 country: United States name: Christopher Chow role: PRINCIPAL_INVESTIGATOR lat: 34.22834 lon: -118.53675 facility: California Liver Research Institute city: Pasadena state: California zip: 91105 country: United States name: Edward Mena role: PRINCIPAL_INVESTIGATOR lat: 34.14778 lon: -118.14452 facility: Western University of Health Sciences city: Pomona state: California zip: 91766 country: United States name: Airani Sathananthan role: PRINCIPAL_INVESTIGATOR lat: 34.05529 lon: -117.75228 facility: California Kidney Specialists city: San Dimas state: California zip: 91773 country: United States name: Aamir Jamal role: PRINCIPAL_INVESTIGATOR lat: 34.10668 lon: -117.80673 facility: Southern California Dermatology, Inc. city: Santa Ana state: California zip: 92701 country: United States name: Wayne Ho role: PRINCIPAL_INVESTIGATOR lat: 33.74557 lon: -117.86783 facility: Encompass Clinical Research city: Spring Valley state: California zip: 91978 country: United States name: Hanid Audish role: PRINCIPAL_INVESTIGATOR lat: 32.74477 lon: -116.99892 facility: Valiance Clinical Research city: Tarzana state: California zip: 91356 country: United States name: Kalpesh Patel role: PRINCIPAL_INVESTIGATOR lat: 34.17334 lon: -118.55397 facility: National Institute of Clinical Research (NICR) - High Desert city: Victorville state: California zip: 92393 country: United States name: Jay Shankar role: PRINCIPAL_INVESTIGATOR lat: 34.53611 lon: -117.29116 facility: Synexus Clinical Research US - Vista city: Vista state: California zip: 92083 country: United States name: Isabel J. Pereira role: PRINCIPAL_INVESTIGATOR lat: 33.20004 lon: -117.24254 facility: Excel Medical Clinical Trials city: Boca Raton state: Florida zip: 33434 country: United States name: Rasha Youssef role: PRINCIPAL_INVESTIGATOR lat: 26.3669 lon: -80.13033 facility: Fleming Island Center for Clinical Research city: Fleming Island state: Florida zip: 32003 country: United States name: Jennifer M Sidey role: PRINCIPAL_INVESTIGATOR lat: 30.0933 lon: -81.71898 facility: Florida Kidney Physicians - Fort Lauderdale city: Fort Lauderdale state: Florida zip: 33316 country: United States name: Zachary Yablon role: PRINCIPAL_INVESTIGATOR lat: 26.12231 lon: -80.14338 facility: Inpatient Research Clinic city: Miami Lakes state: Florida zip: 33014 country: United States name: Alexis Gutierrez role: PRINCIPAL_INVESTIGATOR lat: 25.90871 lon: -80.30866 facility: New Age Medical Research Corporation city: Miami state: Florida zip: 33186 country: United States name: Janet K. Gersten role: PRINCIPAL_INVESTIGATOR lat: 25.77427 lon: -80.19366 facility: Elixia Central Florida city: Orlando state: Florida zip: 32806 country: United States name: Arvind Madan role: PRINCIPAL_INVESTIGATOR lat: 28.53834 lon: -81.37924 facility: Omega Research Orlando city: Orlando state: Florida zip: 32808 country: United States name: Kwabena Ayesu role: PRINCIPAL_INVESTIGATOR lat: 28.53834 lon: -81.37924 facility: Florida Kidney Physicians - Port Charlotte city: Port Charlotte state: Florida zip: 33952 country: United States name: Kianoosh Kaveh role: PRINCIPAL_INVESTIGATOR lat: 26.97617 lon: -82.09064 facility: Florida Kidney Physicians - Tampa city: Riverview state: Florida zip: 33578 country: United States name: Amit Johnsingh role: PRINCIPAL_INVESTIGATOR lat: 27.86614 lon: -82.32648 facility: Palm Harbor Dermatology PA d/b/a TrueBlue Clinical Research city: Tampa state: Florida zip: 33609 country: United States name: Scott E Miller role: PRINCIPAL_INVESTIGATOR lat: 27.94752 lon: -82.45843 facility: American Clinical Trials - Acworth city: Acworth state: Georgia zip: 30101 country: United States name: CHINEDU PATRICK NWEKE role: PRINCIPAL_INVESTIGATOR lat: 34.06635 lon: -84.67837 facility: Atlanta Diabetes Associates city: Atlanta state: Georgia zip: 30318 country: United States name: Bruce Bode role: PRINCIPAL_INVESTIGATOR lat: 33.749 lon: -84.38798 facility: Fides Clinical Research city: Atlanta state: Georgia zip: 30342 country: United States name: Elizabeth Nguyen role: PRINCIPAL_INVESTIGATOR lat: 33.749 lon: -84.38798 facility: Southeastern Clinical Research Institute city: Augusta state: Georgia zip: 30904 country: United States name: Matthew J Diamond role: PRINCIPAL_INVESTIGATOR lat: 33.47097 lon: -81.97484 facility: American Clinical Trials - Douglasville city: Douglasville state: Georgia zip: 30134 country: United States name: Ayorinde Soipe role: PRINCIPAL_INVESTIGATOR lat: 33.7515 lon: -84.74771 facility: Center for Advanced Research & Education city: Gainesville state: Georgia zip: 30501 country: United States name: Angela Dawn Ritter role: PRINCIPAL_INVESTIGATOR lat: 34.29788 lon: -83.82407 facility: East Coast Institute for Research, LLC city: Macon state: Georgia zip: 31210 country: United States name: Thomas Cunningham Jones role: PRINCIPAL_INVESTIGATOR lat: 32.84069 lon: -83.6324 facility: North Georgia Clinical Research city: Woodstock state: Georgia zip: 30189 country: United States name: Bram Wieskopf role: PRINCIPAL_INVESTIGATOR lat: 34.10149 lon: -84.51938 facility: Clinical Investigation Specialists city: Gurnee state: Illinois zip: 60031 country: United States name: Luis Gonzalez-Orozco role: PRINCIPAL_INVESTIGATOR lat: 42.3703 lon: -87.90202 facility: Accellacare - DuPage city: Lombard state: Illinois zip: 60148 country: United States name: Yoko Momoyama role: PRINCIPAL_INVESTIGATOR lat: 41.88003 lon: -88.00784 facility: Alliance for Multispecialty Research, LLC city: Park Ridge state: Illinois zip: 60068 country: United States name: Saifullah Nasir role: PRINCIPAL_INVESTIGATOR lat: 42.01114 lon: -87.84062 facility: Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative city: Springfield state: Illinois zip: 62711 country: United States name: Diana Widicus role: PRINCIPAL_INVESTIGATOR lat: 39.80172 lon: -89.64371 facility: Reid Physician Associates city: Richmond state: Indiana zip: 47374 country: United States name: John Edward McGinty role: PRINCIPAL_INVESTIGATOR lat: 39.82894 lon: -84.89024 facility: Iowa Diabetes and Endocrinology Research Center city: West Des Moines state: Iowa zip: 50265 country: United States name: Anuj Bhargava role: PRINCIPAL_INVESTIGATOR lat: 41.57721 lon: -93.71133 facility: The University of Kansas - Clinical Research Center city: Fairway state: Kansas zip: 66205 country: United States name: Kristine Grdinovac role: PRINCIPAL_INVESTIGATOR lat: 39.02223 lon: -94.6319 facility: Alliance for Multispecialty Research, LLC city: Newton state: Kansas zip: 67114 country: United States name: Richard Glover role: PRINCIPAL_INVESTIGATOR lat: 38.04668 lon: -97.34504 facility: Cotton O'Neil Clinical Research Center - Central Office city: Topeka state: Kansas zip: 66606 country: United States name: Katherine Willingham role: PRINCIPAL_INVESTIGATOR lat: 39.04833 lon: -95.67804 facility: Cotton O'Neil Clinical Research Center city: Topeka state: Kansas zip: 66606 country: United States name: susan brian role: PRINCIPAL_INVESTIGATOR lat: 39.04833 lon: -95.67804 facility: Qualmedica Research city: Bowling Green state: Kentucky zip: 42101 country: United States name: J Christopher Christopher Sartore role: PRINCIPAL_INVESTIGATOR lat: 36.99032 lon: -86.4436 facility: L-MARC Research Center city: Louisville state: Kentucky zip: 40213 country: United States name: Harold E. Bays role: PRINCIPAL_INVESTIGATOR lat: 38.25424 lon: -85.75941 facility: Cambridge Medical Trials city: Alexandria state: Louisiana zip: 71301 country: United States name: Naseem Jaffrani role: PRINCIPAL_INVESTIGATOR lat: 31.31129 lon: -92.44514 facility: IMA Clinical Research Monroe - Armand city: Monroe state: Louisiana zip: 71201 country: United States name: Clinton Guillory role: PRINCIPAL_INVESTIGATOR lat: 32.50931 lon: -92.1193 facility: Alliance for Multispecialty Research, LLC city: New Orleans state: Louisiana zip: 70119 country: United States name: Robert J Noveck role: PRINCIPAL_INVESTIGATOR lat: 29.95465 lon: -90.07507 facility: Maryland Cardiovascular Specialists city: Baltimore state: Maryland zip: 21229 country: United States name: Jeffrey F. Cole role: PRINCIPAL_INVESTIGATOR lat: 39.29038 lon: -76.61219 facility: Joslin Diabetes Center city: Boston state: Massachusetts zip: 02215 country: United States name: Osama Hamdy role: PRINCIPAL_INVESTIGATOR lat: 42.35843 lon: -71.05977 facility: NECCR PrimaCare Research city: Fall River state: Massachusetts zip: 02721 country: United States name: Ehab Sorial role: PRINCIPAL_INVESTIGATOR lat: 41.70149 lon: -71.15505 facility: Alliance for Multispecialty Research, LLC. city: Dearborn state: Michigan zip: 48126 country: United States name: Elias H Kassab role: PRINCIPAL_INVESTIGATOR lat: 42.32226 lon: -83.17631 facility: Revival Research Institute - Dearborn city: Dearborn state: Michigan zip: 48126 country: United States name: Qaiser Shafiq role: PRINCIPAL_INVESTIGATOR lat: 42.32226 lon: -83.17631 facility: Elixia MKC, LLC city: Pontiac state: Michigan zip: 48341 country: United States name: Fahd Al-Saghir role: PRINCIPAL_INVESTIGATOR lat: 42.63892 lon: -83.29105 facility: St. Clair Nephrology city: Shelby state: Michigan zip: 48315 country: United States name: Joel Michels Topf role: PRINCIPAL_INVESTIGATOR lat: 42.67087 lon: -83.03298 facility: Arcturus Healthcare , PLC, Troy Internal Medicine Research Division city: Troy state: Michigan zip: 48098 country: United States name: Neil J. Fraser role: PRINCIPAL_INVESTIGATOR lat: 42.60559 lon: -83.14993 facility: Alliance for Multispecialty Research, LLC city: Kansas City state: Missouri zip: 64114 country: United States name: Martha Sue Fanning role: PRINCIPAL_INVESTIGATOR lat: 39.09973 lon: -94.57857 facility: Mercy Research - Smith Glynn Callaway city: Springfield state: Missouri zip: 65807 country: United States name: Gregory Ledger role: PRINCIPAL_INVESTIGATOR lat: 37.21533 lon: -93.29824 facility: Mercury Street Medical Group, PLLC city: Butte state: Montana zip: 59701 country: United States name: John Pullman role: PRINCIPAL_INVESTIGATOR lat: 46.00382 lon: -112.53474 facility: Boeson Research MSO city: Missoula state: Montana zip: 59804 country: United States name: Aubrey May Remmers role: PRINCIPAL_INVESTIGATOR lat: 46.87215 lon: -113.994 facility: DaVita Clinical Research - Las Vegas city: Las Vegas state: Nevada zip: 89107 country: United States name: MARK VISHNEPOLSKY role: PRINCIPAL_INVESTIGATOR lat: 36.17497 lon: -115.13722 facility: Long Island Cardiovascular Consultants city: Lake Success state: New York zip: 11042 country: United States name: Kenneth Cohen role: PRINCIPAL_INVESTIGATOR lat: 40.77066 lon: -73.71763 facility: Northwell Health Physician Peconic city: Riverhead state: New York zip: 11901 country: United States name: Sean M Donahoe role: PRINCIPAL_INVESTIGATOR lat: 40.91704 lon: -72.66204 facility: Medication Management city: Greensboro state: North Carolina zip: 27405 country: United States name: Jagadeesh (Jay) R. Ganji role: PRINCIPAL_INVESTIGATOR lat: 36.07264 lon: -79.79198 facility: IMA Clinical Research - Lenoir city: Lenoir state: North Carolina zip: 28645 country: United States name: Johnny Dy role: PRINCIPAL_INVESTIGATOR lat: 35.91402 lon: -81.53898 facility: West Clinical Research city: Morehead City state: North Carolina zip: 28557 country: United States name: Patrick Morgante role: PRINCIPAL_INVESTIGATOR lat: 34.72294 lon: -76.72604 facility: Accellacare - Raleigh city: Raleigh state: North Carolina zip: 27609 country: United States name: John Rubino role: PRINCIPAL_INVESTIGATOR lat: 35.7721 lon: -78.63861 facility: Accellacare - Wilmington - 1917 Tradd Court city: Wilmington state: North Carolina zip: 28401 country: United States name: John Charles Parker role: PRINCIPAL_INVESTIGATOR lat: 34.22573 lon: -77.94471 facility: Guthrie Medical Group, P.C. city: Sayre state: Pennsylvania zip: 18840 country: United States name: Sahzene Yavuz role: PRINCIPAL_INVESTIGATOR lat: 41.97896 lon: -76.5155 facility: Clinical Renal Associates - Panoramic Science city: Upland state: Pennsylvania zip: 19013 country: United States name: Chike Nathan Okechukwu role: PRINCIPAL_INVESTIGATOR lat: 39.85261 lon: -75.38269 facility: Accellacare Trident Cardiology city: Charleston state: South Carolina zip: 29456 country: United States name: William D Yarbrough role: PRINCIPAL_INVESTIGATOR lat: 32.77657 lon: -79.93092 facility: Walker Family Care city: Little River state: South Carolina zip: 29566 country: United States name: Stephen Dale Grubb role: PRINCIPAL_INVESTIGATOR lat: 33.87323 lon: -78.61418 facility: South Carolina Clinical Research LLC city: Orangeburg state: South Carolina zip: 29118 country: United States name: Moustafa Ashraf Hamed Moustafa role: PRINCIPAL_INVESTIGATOR lat: 33.49182 lon: -80.85565 facility: Circle Clinical Research city: Sioux Falls state: South Dakota zip: 57104 country: United States name: Elizabeth Jensen role: PRINCIPAL_INVESTIGATOR lat: 43.54997 lon: -96.70033 facility: Alliance for Multispecialty Research, LLC city: Knoxville state: Tennessee zip: 37920 country: United States name: William B. Smith role: PRINCIPAL_INVESTIGATOR lat: 35.96064 lon: -83.92074 facility: Care Access - Memphis city: Memphis state: Tennessee zip: 38128 country: United States name: Joseph Seth Weinstein role: PRINCIPAL_INVESTIGATOR lat: 35.14953 lon: -90.04898 facility: IMA Clinical Research Austin city: Austin state: Texas zip: 78745 country: United States name: Nomita Kim role: PRINCIPAL_INVESTIGATOR lat: 30.26715 lon: -97.74306 facility: Headlands Research - Brownsville city: Brownsville state: Texas zip: 78526 country: United States name: Christopher Romero role: PRINCIPAL_INVESTIGATOR lat: 25.90175 lon: -97.49748 facility: South Texas Clinical Research city: Corpus Christi state: Texas zip: 78404 country: United States name: Travis Taylor role: PRINCIPAL_INVESTIGATOR lat: 27.80058 lon: -97.39638 facility: Baylor Soltero CV Research Center city: Dallas state: Texas zip: 75226 country: United States name: Cara East role: PRINCIPAL_INVESTIGATOR lat: 32.78306 lon: -96.80667 facility: Renal Disease Research Institute city: Dallas state: Texas zip: 75246 country: United States name: Bernard Fischbach role: PRINCIPAL_INVESTIGATOR lat: 32.78306 lon: -96.80667 facility: South Texas Research Institute city: Edinburg state: Texas zip: 78539 country: United States name: Rashmee Patil role: PRINCIPAL_INVESTIGATOR lat: 26.30174 lon: -98.16334 facility: El Paso Medical Research Institute city: El Paso state: Texas zip: 79902-4646 country: United States name: Javier Vasallo role: PRINCIPAL_INVESTIGATOR lat: 31.75872 lon: -106.48693 facility: Diabetes and Thyroid Center of Ft. Worth city: Fort Worth state: Texas zip: 76132 country: United States name: Anjanette Tan role: PRINCIPAL_INVESTIGATOR lat: 32.72541 lon: -97.32085 facility: Valley Institute of Research - Fort Worth city: Fort Worth state: Texas zip: 76164 country: United States name: alex guevara role: PRINCIPAL_INVESTIGATOR lat: 32.72541 lon: -97.32085 facility: Aqua Research Institute city: Houston state: Texas zip: 77058 country: United States name: Justin David Merszei role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 facility: Northwest Houston Cardiology - Cypress city: Houston state: Texas zip: 77070 country: United States name: Aditya Samal role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 facility: Clinical Trial Network city: Houston state: Texas zip: 77074 country: United States name: Ritesh Mathur role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 facility: Endocrine Ips, Pllc city: Houston state: Texas zip: 77079 country: United States name: Prashant G Koshy role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 facility: Amir A Hassan, MD, PA city: Houston state: Texas zip: 77089 country: United States name: Amir Ali Hassan, MD role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 facility: Accurate Clinical Research, Inc city: Humble state: Texas zip: 77346 country: United States name: Brian Yuan Chou role: PRINCIPAL_INVESTIGATOR lat: 29.99883 lon: -95.26216 facility: Texas Institute for Kidney and Endocrine Disorders city: Lufkin state: Texas zip: 75904 country: United States name: Lance A Sloan role: PRINCIPAL_INVESTIGATOR lat: 31.33824 lon: -94.7291 facility: Wellness Clinical Research city: McKinney state: Texas zip: 75069 country: United States name: Zahid Zafar role: PRINCIPAL_INVESTIGATOR lat: 33.19762 lon: -96.61527 facility: PRX Research city: Mesquite state: Texas zip: 75149 country: United States name: Samer Nachawati role: PRINCIPAL_INVESTIGATOR lat: 32.7668 lon: -96.59916 facility: National Institute of Clinical Research (NICR) - San Antonio - South Laredo Street city: San Antonio state: Texas zip: 78204 country: United States name: Robert G. Szewc role: PRINCIPAL_INVESTIGATOR lat: 29.42412 lon: -98.49363 facility: Clinical Advancement Center city: San Antonio state: Texas zip: 78212 country: United States name: Pablo E Pergola role: PRINCIPAL_INVESTIGATOR lat: 29.42412 lon: -98.49363 facility: Diagnostics Research Group city: San Antonio state: Texas zip: 78229 country: United States name: Lisa J Blair role: PRINCIPAL_INVESTIGATOR lat: 29.42412 lon: -98.49363 facility: Endeavor Clinical Trials city: San Antonio state: Texas zip: 78240 country: United States name: Nitendra Agarwal role: PRINCIPAL_INVESTIGATOR lat: 29.42412 lon: -98.49363 facility: DaVita Clinical Research - North Houston city: Shenandoah state: Texas zip: 77384 country: United States name: Adam Immanuel Frome role: PRINCIPAL_INVESTIGATOR lat: 30.18022 lon: -95.45577 facility: Revival Research Institute, LLC city: Sherman state: Texas zip: 75092 country: United States name: Syed Saghir role: PRINCIPAL_INVESTIGATOR lat: 33.63566 lon: -96.60888 facility: Medrasa Clinical Research city: Wylie state: Texas zip: 75098 country: United States name: Tanvir Ahmad role: PRINCIPAL_INVESTIGATOR lat: 33.01512 lon: -96.53888 facility: Alpine Research Organization city: Clinton state: Utah zip: 84015 country: United States name: Justin Mansfield role: PRINCIPAL_INVESTIGATOR lat: 41.13967 lon: -112.0505 facility: Alliance for Multispecialty Research, LLC city: Layton state: Utah zip: 84041 country: United States name: Craig K. Julien role: PRINCIPAL_INVESTIGATOR lat: 41.06022 lon: -111.97105 facility: Synexus Clinical Research US, Inc. city: Salt Lake City state: Utah zip: 84106 country: United States name: Michael Adams role: PRINCIPAL_INVESTIGATOR lat: 40.76078 lon: -111.89105 facility: Utah Kidney Research Institute city: Salt Lake City state: Utah zip: 84115 country: United States name: Sanjiv Anand role: PRINCIPAL_INVESTIGATOR lat: 40.76078 lon: -111.89105 facility: Alliance for Multispecialty Research, LLC city: Norfolk state: Virginia zip: 23502 country: United States name: Mary C. L. Bailey role: PRINCIPAL_INVESTIGATOR lat: 36.84681 lon: -76.28522 facility: Eastside Research Associates city: Redmond state: Washington zip: 98052 country: United States name: Kevin Michael Hanson role: PRINCIPAL_INVESTIGATOR lat: 47.67399 lon: -122.12151 facility: Universal Research Group city: Tacoma state: Washington zip: 98405 country: United States name: Sabrina Ann Benjamin role: PRINCIPAL_INVESTIGATOR lat: 47.25288 lon: -122.44429 facility: IMA Clinical Research city: Morgantown state: West Virginia zip: 26505 country: United States name: WARD J PAINE role: PRINCIPAL_INVESTIGATOR lat: 39.62953 lon: -79.9559 facility: St. Vincent Hospital d/b/a Prevea Health city: Green Bay state: Wisconsin zip: 54303 country: United States name: Aliaksandr Trusau role: PRINCIPAL_INVESTIGATOR lat: 44.51916 lon: -88.01983 facility: Clinical Investigation Specialists city: Kenosha state: Wisconsin zip: 53144 country: United States name: Bharathi Pulla role: PRINCIPAL_INVESTIGATOR lat: 42.58474 lon: -87.82119 facility: IDIM - Instituto de Diagnóstico e Investigaciones Metabólicas city: Ciudad de Buenos Aires state: Buenos Aires zip: C1012AAR country: Argentina name: Santiago Oscar Bruzone role: PRINCIPAL_INVESTIGATOR lat: -34.61315 lon: -58.37723 facility: Centro Médico Lebensohn city: Junín state: Buenos Aires zip: 6000 country: Argentina name: Maria José Pelagagge role: PRINCIPAL_INVESTIGATOR lat: -34.58382 lon: -60.94332 facility: Hospital Italiano de La Plata city: La Plata state: Buenos Aires zip: 1900 country: Argentina name: Matías Re role: PRINCIPAL_INVESTIGATOR lat: -34.92145 lon: -57.95453 facility: Clínica Privada Independencia city: Munro state: Buenos Aires zip: 1605 country: Argentina name: Maan Sarem role: PRINCIPAL_INVESTIGATOR lat: -34.53021 lon: -58.52421 facility: Instituto De Investigaciones Clinicas Quilmes city: Quilmes state: Buenos Aires zip: 1878 country: Argentina name: Adrian Hrabar role: PRINCIPAL_INVESTIGATOR lat: -34.72904 lon: -58.26374 facility: Stat Research S.A. city: Buenos Aires state: Ciudad Autónoma De Buenos Aires zip: C1023AAB country: Argentina name: Lucas Lisandro Gutnisky role: PRINCIPAL_INVESTIGATOR lat: -34.61315 lon: -58.37723 facility: Investigaciones Medicas Imoba Srl city: Buenos Aires state: Ciudad Autónoma De Buenos Aires zip: C1056ABH country: Argentina name: Silvia Ines Orio role: PRINCIPAL_INVESTIGATOR lat: -34.61315 lon: -58.37723 facility: Centro Médico Viamonte city: Buenos Aires state: Ciudad Autónoma De Buenos Aires zip: C1120AAC country: Argentina name: Diego Aizenberg role: PRINCIPAL_INVESTIGATOR lat: -34.61315 lon: -58.37723 facility: Mautalen Salud e Investigación city: Buenos Aires state: Ciudad Autónoma De Buenos Aires zip: C1128AAF country: Argentina name: José Osvaldo Fretes role: PRINCIPAL_INVESTIGATOR lat: -34.61315 lon: -58.37723 facility: CEMEDIAB city: C.a.b.a. state: Ciudad Autónoma De Buenos Aires zip: C1205AAO country: Argentina name: Alejandro Mario Chertkoff role: PRINCIPAL_INVESTIGATOR lat: -34.61315 lon: -58.37723 facility: Consultorio de Investigación Clínica EMO SRL city: Ciudad Autonoma de Buenos Aires state: Ciudad Autónoma De Buenos Aires zip: 1405 country: Argentina name: Pablo Rene Costanzo role: PRINCIPAL_INVESTIGATOR lat: -34.61315 lon: -58.37723 facility: Instituto Médico Río Cuarto city: Río Cuarto state: Córdoba zip: X5800AEV country: Argentina name: Rodrigo Carnero role: PRINCIPAL_INVESTIGATOR lat: -33.13067 lon: -64.34992 facility: Centro de Salud e Investigaciones Médicas city: Santa Rosa state: La Pampa zip: 6300 country: Argentina name: Marcos Alejandro Mayer role: PRINCIPAL_INVESTIGATOR lat: -36.61667 lon: -64.28333 facility: Polo de Salud Vistalba city: Luján de Cuyo state: Mendoza zip: 5509 country: Argentina name: Cristian Hernan Lecussan role: PRINCIPAL_INVESTIGATOR lat: -33.03547 lon: -68.87782 facility: Instituto de Especialidades de la Salud Rosario city: Rosario state: Santa Fe zip: 2000 country: Argentina name: Ana Elisa Chiesa role: PRINCIPAL_INVESTIGATOR lat: -32.94682 lon: -60.63932 facility: Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Medica city: Rosario state: Santa Fe zip: 2000 country: Argentina name: Horacio Angel Sessa role: PRINCIPAL_INVESTIGATOR lat: -32.94682 lon: -60.63932 facility: Hospital Provincial del Centenario city: Rosario state: Santa Fe zip: S2002KDS country: Argentina name: Martin Najenson role: PRINCIPAL_INVESTIGATOR lat: -32.94682 lon: -60.63932 facility: Sanatorio San Martin city: Venado Tuerto state: Santa Fe zip: 2600 country: Argentina name: Oscar Gomez Vilamajo role: PRINCIPAL_INVESTIGATOR lat: -33.74556 lon: -61.96885 facility: Centro de Investigaciones Médicas Tucuman city: SAN M. DE Tucuman state: Tucumán zip: T4000AXL country: Argentina name: Leonardo Pablo Serra role: PRINCIPAL_INVESTIGATOR facility: CONEXA Investigacion Clinica S.A. city: Buenos Aires zip: 1012 country: Argentina name: María Florencia Scioscia role: PRINCIPAL_INVESTIGATOR lat: -34.61315 lon: -58.37723 facility: Buenos Aires Macula S.A city: Buenos Aires zip: 1061 country: Argentina name: Adrian Proietti role: PRINCIPAL_INVESTIGATOR lat: -34.61315 lon: -58.37723 facility: Instituto Médico Especializado (IME) city: Buenos Aires zip: 1405 country: Argentina name: Patricia Mabel Castaño role: PRINCIPAL_INVESTIGATOR lat: -34.61315 lon: -58.37723 facility: Cardiología Palermo city: Buenos Aires zip: 1425 country: Argentina name: Paula Perez Terns role: PRINCIPAL_INVESTIGATOR lat: -34.61315 lon: -58.37723 facility: Sanatorio Privado Duarte Quirós city: Córdoba zip: 5002 country: Argentina name: Hugo Raul Colombo role: PRINCIPAL_INVESTIGATOR lat: -31.4135 lon: -64.18105 facility: Centro de Diagnóstico y Rehabilitación (CEDIR) city: Santa Fe zip: 3000 country: Argentina name: Antonio Enrique Saleme role: PRINCIPAL_INVESTIGATOR lat: -31.63333 lon: -60.7 facility: Clínica de Nefrología, Urología y Enfermedades Cardiovasculares city: Santa Fe zip: 3000 country: Argentina name: MARIA GUILLERMINA BEVILACQUA role: PRINCIPAL_INVESTIGATOR lat: -31.63333 lon: -60.7 facility: Centro de Investigaciones Clinicas del Litoral city: Santa Fe zip: S3000FWO country: Argentina name: Miguel Hominal role: PRINCIPAL_INVESTIGATOR lat: -31.63333 lon: -60.7 facility: Sanatorio Norte city: Santiago del Estero zip: 4200 country: Argentina name: Franklin Hector Abalos role: PRINCIPAL_INVESTIGATOR lat: -27.79511 lon: -64.26149 facility: Optimus Clinical Research city: Botany state: New South Wales zip: 2019 country: Australia name: Paul Bird role: PRINCIPAL_INVESTIGATOR lat: -33.94599 lon: 151.19591 facility: Northern Beaches Clinical Research city: Brookvale state: New South Wales zip: 2100 country: Australia name: Richard de Solom role: PRINCIPAL_INVESTIGATOR lat: -33.76108 lon: 151.27446 facility: The AIM Centre / Hunter Diabetes Centre city: Merewether state: New South Wales zip: 2291 country: Australia name: Claire Morbey role: PRINCIPAL_INVESTIGATOR lat: -32.94801 lon: 151.74325 facility: Nightingale Research city: Adelaide state: South Australia zip: 5000 country: Australia name: Andrew Hamilton role: PRINCIPAL_INVESTIGATOR lat: -34.92866 lon: 138.59863 facility: Emeritus Research city: Camberwell state: Victoria zip: 3124 country: Australia name: Stuart Game role: PRINCIPAL_INVESTIGATOR lat: -37.84205 lon: 145.0694 facility: Zentrum für klinische Studien Dr Hanusch Gmbh city: Vienna state: Wien zip: 1060 country: Austria name: Ursula Hanusch role: PRINCIPAL_INVESTIGATOR lat: 48.20849 lon: 16.37208 facility: Centro de Pesquisas Clínicas Dr. Marco Mota city: Maceio state: Alagoas zip: 57051-160 country: Brazil name: Marco Antonio Mota Gomes role: PRINCIPAL_INVESTIGATOR lat: -9.66583 lon: -35.73528 facility: CPHOSP Manaus Medicina, Ensino e Pesquisa city: Manaus state: Amazonas zip: 69057-088 country: Brazil name: Gustavo Akerman Augusto role: PRINCIPAL_INVESTIGATOR lat: -3.10194 lon: -60.025 facility: L2IP - Instituto de Pesquisas Clínicas - FC072920211954380192 city: Brasília state: Distrito Federal zip: 70200730 country: Brazil name: Eduardo Freire Vasconcellos role: PRINCIPAL_INVESTIGATOR lat: -15.77972 lon: -47.92972 facility: Consultoria em Controle de Infecção Hospitalar city: Belo Horizonte state: Minas Gerais zip: 30150-320 country: Brazil name: Flávia Coimbra Maia role: PRINCIPAL_INVESTIGATOR lat: -19.92083 lon: -43.93778 facility: Eurolatino Pesquisas Medicas city: Uberlandia state: Minas Gerais zip: 38400-500 country: Brazil name: Flavia Arantes role: PRINCIPAL_INVESTIGATOR lat: -18.91861 lon: -48.27722 facility: PUC Trials- Nucleo de Pesquisa clinica da Escola de Medicina da PUCPR city: Curitiba state: Paraná zip: 80230-130 country: Brazil name: Jose Fortes role: PRINCIPAL_INVESTIGATOR lat: -25.42778 lon: -49.27306 facility: Centro de Endocrinologia Geloneze city: Campinas state: São Paulo zip: 13073-350 country: Brazil name: Bruno Geloneze role: PRINCIPAL_INVESTIGATOR lat: -22.90556 lon: -47.06083 facility: IBPClin - Instituto Brasil de Pesquisa Clínica city: Rio de Janeiro zip: 20241-180 country: Brazil name: JOSELITA BODART role: PRINCIPAL_INVESTIGATOR lat: -22.90278 lon: -43.2075 facility: Ruschel Medicina e Pesquisa Clínica city: Rio De Janeiro zip: 22270-060 country: Brazil name: Luiza Siffert role: PRINCIPAL_INVESTIGATOR lat: -22.90278 lon: -43.2075 facility: Hospital Pro-Cardiaco city: Rio de Janeiro zip: 22280-003 country: Brazil name: Diane Avila role: PRINCIPAL_INVESTIGATOR lat: -22.90278 lon: -43.2075 facility: CPQuali Pesquisa Clínica city: São Paulo zip: 01228-000 country: Brazil name: Gustavo Akerman Augusto role: PRINCIPAL_INVESTIGATOR lat: -23.5475 lon: -46.63611 facility: Núcleo de Pesquisa Clínica da Rede São Camilo city: São Paulo zip: 04014-002 country: Brazil name: Luana Casari da Silva Lima role: PRINCIPAL_INVESTIGATOR lat: -23.5475 lon: -46.63611 facility: SMH Cardiology Clinical Trials city: Surrey state: British Columbia zip: V3V 0C6 country: Canada name: Kapil Bhagirath role: PRINCIPAL_INVESTIGATOR lat: 49.10635 lon: -122.82509 facility: Winnipeg Clinic city: Winnipeg state: Manitoba zip: R3C 0N2 country: Canada name: Vincent Woo role: PRINCIPAL_INVESTIGATOR lat: 49.8844 lon: -97.14704 facility: G A Research Associates city: Moncton state: New Brunswick zip: E1G 1A7 country: Canada name: Jocelyn Cormier role: PRINCIPAL_INVESTIGATOR lat: 46.09454 lon: -64.7965 facility: Care Access - Cape Breton city: Sydney state: Nova Scotia zip: B1M 0A1 country: Canada name: Tony Valente role: PRINCIPAL_INVESTIGATOR lat: 46.13511 lon: -60.1831 facility: Western Centre for Public Health and Family Medicine city: London state: Ontario zip: N6G 2M1 country: Canada name: Stewart Harris role: PRINCIPAL_INVESTIGATOR lat: 42.98339 lon: -81.23304 facility: North York Diagnostic and Cardiac Centre city: North York state: Ontario zip: M6B 3H7 country: Canada name: Subodh Verma role: PRINCIPAL_INVESTIGATOR lat: 43.76681 lon: -79.4163 facility: Lakeridge Health city: Oshawa state: Ontario zip: L1G 2B9 country: Canada name: Andrew Steele role: PRINCIPAL_INVESTIGATOR lat: 43.90012 lon: -78.84957 facility: Unité de Recherche Clinique du CISSS des Laurentides city: St-Jerome state: Quebec zip: J7Z 2V4 country: Canada name: Yves Pesant role: PRINCIPAL_INVESTIGATOR lat: 45.78036 lon: -74.00365 facility: UNIVMED city: Brno state: Brno-město zip: 602 00 country: Czechia name: Ota Hlinomaz role: PRINCIPAL_INVESTIGATOR lat: 49.19522 lon: 16.60796 facility: Fakultni Nemocnice u sv. Anny v Brne city: Brno state: Jihomoravský Kraj zip: 602 00 country: Czechia name: Robert Prosecky role: PRINCIPAL_INVESTIGATOR lat: 49.19522 lon: 16.60796 facility: Kardio Chlumec city: Chlumec nad Cidlinou state: Královéhradecký Kraj zip: 503 51 country: Czechia name: Martin Wiendl role: PRINCIPAL_INVESTIGATOR lat: 50.1544 lon: 15.46026 facility: MaderMED city: Ostrava state: Moravskoslezský Kraj zip: 710 00 country: Czechia name: David Maderic role: PRINCIPAL_INVESTIGATOR lat: 49.83465 lon: 18.28204 facility: Kardiologicka ambulance city: Litovel state: Olomoucký Kraj zip: 784 01 country: Czechia name: Petra Maskova role: PRINCIPAL_INVESTIGATOR lat: 49.70121 lon: 17.07615 facility: Agentura Science Pro city: Olomouc state: Olomoucký Kraj zip: 779 00 country: Czechia name: Tomas Brychta role: PRINCIPAL_INVESTIGATOR lat: 49.59552 lon: 17.25175 facility: Private Practice - Dr. Miroslav Koliba city: Ostrava state: Ostrava Město zip: 702 00 country: Czechia name: Miroslav Koliba role: PRINCIPAL_INVESTIGATOR lat: 49.83465 lon: 18.28204 facility: Diakom, s.r.o. - Přeštice city: Přeštice state: Plzeň-jih zip: 334 01 country: Czechia name: Renata Arias role: PRINCIPAL_INVESTIGATOR lat: 49.57298 lon: 13.3335 facility: MUDr. Jana Parkanyiova city: Prague state: Praha 1 zip: 110 00 country: Czechia name: Jana Kostarova role: PRINCIPAL_INVESTIGATOR lat: 50.08804 lon: 14.42076 facility: Synexus Czech city: Prague state: Praha 2 zip: 120 00 country: Czechia name: Iva Skarpova role: PRINCIPAL_INVESTIGATOR lat: 50.08804 lon: 14.42076 facility: MEDICON city: Prague state: Praha 4 zip: 140 00 country: Czechia name: Drahomira Gulakova role: PRINCIPAL_INVESTIGATOR lat: 50.08804 lon: 14.42076 facility: Fakultni Thomayerova nemocnice city: Prague state: Praha 4 zip: 14059 country: Czechia name: Jiri Skopek role: PRINCIPAL_INVESTIGATOR lat: 50.08804 lon: 14.42076 facility: Nefrologie city: Prague state: Praha 4 zip: 149 00 country: Czechia name: Lucie Hornova role: PRINCIPAL_INVESTIGATOR lat: 50.08804 lon: 14.42076 facility: DiaVize s.r.o. city: Praha state: Praha 4 zip: 140 00 country: Czechia name: Marta Klementova role: PRINCIPAL_INVESTIGATOR lat: 50.08804 lon: 14.42076 facility: Centrum Kardiovaskularni Mediciny city: Prague state: Praha 6 zip: 169 00 country: Czechia name: Jean-Claude Lubanda role: PRINCIPAL_INVESTIGATOR lat: 50.08804 lon: 14.42076 facility: ResTrial s.r.o. city: Praha state: Praha 8 zip: 18100 country: Czechia name: Emilia Malicherova role: PRINCIPAL_INVESTIGATOR lat: 50.08804 lon: 14.42076 facility: MUDr. Barbora Diepoltova city: Praha 9 - Klanovice state: Praha 9 zip: 190 14 country: Czechia name: Barbora Diepoltova role: PRINCIPAL_INVESTIGATOR lat: 50.08804 lon: 14.42076 facility: FLEDIP - Na dlouhem lanu city: Prague state: Praha, Hlavní Mešto zip: 160 00 country: Czechia name: Milan Flekac role: PRINCIPAL_INVESTIGATOR lat: 50.08804 lon: 14.42076 facility: Diabetologie a endokrinologie, J.Venerová city: Praha 6 state: Praha, Hlavní Mešto zip: 169 00 country: Czechia name: Johana Venerova role: PRINCIPAL_INVESTIGATOR lat: 50.08804 lon: 14.42076 facility: Kardiologicka ambulance city: Brandýs nad Labem-Stará Boleslav state: Praha-východ zip: 250 01 country: Czechia name: Jiri Krupicka role: PRINCIPAL_INVESTIGATOR lat: 50.18709 lon: 14.66326 facility: Kardioma city: Kolin state: Středočeský Kraj zip: 280 02 country: Czechia name: Vit Maratka role: PRINCIPAL_INVESTIGATOR lat: 50.02806 lon: 15.1998 facility: Clinical Trials Service s.r.o. city: Uherské Hradiště state: Zlínský Kraj zip: 686 01 country: Czechia name: Vladimir Cech role: PRINCIPAL_INVESTIGATOR lat: 49.06975 lon: 17.45969 facility: EDUMED - Náchod city: Náchod zip: 547 01 country: Czechia name: Alica Vesela role: PRINCIPAL_INVESTIGATOR lat: 50.4167 lon: 16.16289 facility: Diabetologicke centrum s.r.o. city: Olomouc zip: 779 00 country: Czechia name: KATARINA NOVAKOVA role: PRINCIPAL_INVESTIGATOR lat: 49.59552 lon: 17.25175 facility: Kardiologicka ambulance MUDr. Ferkl s.r.o. city: Trutnov zip: 541 01 country: Czechia name: Richard Ferkl role: PRINCIPAL_INVESTIGATOR lat: 50.56101 lon: 15.9127 facility: Cardio Research, s.r.o city: Zlín zip: 760 01 country: Czechia name: Tomas Fiala role: PRINCIPAL_INVESTIGATOR lat: 49.22645 lon: 17.67065 facility: Sanos Clinic - Nordjylland city: Gandrup state: Nordjylland zip: 9362 country: Denmark name: Helene Rovsing role: PRINCIPAL_INVESTIGATOR lat: 56.74249 lon: 9.82298 facility: Polyclinique Vauban city: Valenciennes state: Nord zip: 59300 country: France name: Sebastien Caudmont role: PRINCIPAL_INVESTIGATOR lat: 50.35 lon: 3.53333 facility: CRS Clinical Research Services Mannheim city: Mannheim state: Baden-Württemberg zip: 68167 country: Germany name: Thomas Forst role: PRINCIPAL_INVESTIGATOR lat: 49.4891 lon: 8.46694 facility: Nephrologisches Zentrum Villingen-Schwenningen city: Villingen-Schwenningen state: Baden-Württemberg zip: 78052 country: Germany name: Bernd Hohenstein role: PRINCIPAL_INVESTIGATOR lat: 48.06226 lon: 8.49358 facility: Praxis Sauter & Sauter & Vorbach city: Wangen im Allgäu state: Baden-Württemberg zip: 88239 country: Germany name: Joachim Sauter role: PRINCIPAL_INVESTIGATOR lat: 47.6895 lon: 9.83247 facility: ZKS Suedbrandenburg city: Elsterwerda state: Brandenburg zip: 04910 country: Germany name: Andreas n.a. Hagenow role: PRINCIPAL_INVESTIGATOR lat: 51.46043 lon: 13.52001 facility: Kerckhoff-Klinik city: Bad Nauheim state: Hessen zip: 61231 country: Germany name: Roland Klingenberg role: PRINCIPAL_INVESTIGATOR lat: 50.36463 lon: 8.73859 facility: Zentrum für Nieren-, Hochdruck- und Stoffwechselerkrankungen - Heidering city: Hannover state: Niedersachsen zip: 30625 country: Germany name: Georg Schlieper role: PRINCIPAL_INVESTIGATOR lat: 52.37052 lon: 9.73322 facility: Kardiologische Praxis Papenburg city: Papenburg state: Niedersachsen zip: 26871 country: Germany name: Andreas Wilke role: PRINCIPAL_INVESTIGATOR lat: 53.07738 lon: 7.40444 facility: Herz - und Diabeteszentrum Nordrhein - Westfalen, Bad Oeynhausen city: Bad Oeynhausen state: Nordrhein-Westfalen zip: 32545 country: Germany name: Michael Hauber role: PRINCIPAL_INVESTIGATOR lat: 52.20699 lon: 8.80365 facility: InnoDiab Forschung Gmbh city: Essen state: Nordrhein-Westfalen zip: 45136 country: Germany name: Helga Zeller-Stefan role: PRINCIPAL_INVESTIGATOR lat: 51.45657 lon: 7.01228 facility: Unterfrintroper Hausarztzentrum Klinische Forschung city: Essen state: Nordrhein-Westfalen zip: 45359 country: Germany name: Georg Plaßmann role: PRINCIPAL_INVESTIGATOR lat: 51.45657 lon: 7.01228 facility: Institut für Diabetesforschung GmbH Münster city: Münster state: Nordrhein-Westfalen zip: 48145 country: Germany name: Ludger Rose role: PRINCIPAL_INVESTIGATOR lat: 51.96236 lon: 7.62571 facility: Zentrum für klinische Studien city: Saint Ingbert state: Saarland zip: 66386 country: Germany name: Alexander Segner role: PRINCIPAL_INVESTIGATOR facility: Hausärztlich-Kardiologisches MVZ am Felsenkeller GmbH/Zentrum für klinische Studien city: Dresden state: Sachsen zip: 01277 country: Germany name: Christoph Axthelm role: PRINCIPAL_INVESTIGATOR lat: 51.05089 lon: 13.73832 facility: AmBeNet GmbH city: Leipzig state: Sachsen zip: 04107 country: Germany name: Hans-Detlev Stahl role: PRINCIPAL_INVESTIGATOR lat: 51.33962 lon: 12.37129 facility: Universität zu Lübeck - Institut für Endokrinologie und Diabetes city: Lübeck state: Schleswig-Holstein zip: 23562 country: Germany name: Svenja Meyhöfer role: PRINCIPAL_INVESTIGATOR lat: 53.86893 lon: 10.68729 facility: RED-Institut GmbH city: Oldenburg state: Schleswig-Holstein zip: 23758 country: Germany name: Thomas Schaum role: PRINCIPAL_INVESTIGATOR lat: 53.14118 lon: 8.21467 facility: emovis GmbH city: Berlin zip: 10629 country: Germany name: Kerstin Sturm role: PRINCIPAL_INVESTIGATOR lat: 52.52437 lon: 13.41053 facility: Kardiologisch-Angiologische Praxis - Herzzentrum Bremen city: Bremen zip: 28277 country: Germany name: Ertan Dogu role: PRINCIPAL_INVESTIGATOR lat: 53.07516 lon: 8.80777 facility: Diabetes Zentrum Wilhelmsburg city: Hamburg zip: 21109 country: Germany name: Peter Witzel role: PRINCIPAL_INVESTIGATOR lat: 53.57532 lon: 10.01534 facility: Diabetes Zentrum Wandsbek city: Hamburg zip: 22041 country: Germany name: Thorsten Koch role: PRINCIPAL_INVESTIGATOR lat: 53.57532 lon: 10.01534 facility: Allergo-Derm Bakos Kft city: Szolnok state: Jász-Nagykun-Szolnok zip: 5000 country: Hungary name: Noemi Bakos role: PRINCIPAL_INVESTIGATOR lat: 47.18333 lon: 20.2 facility: CRU Early Phase Unit city: Kistarcsa state: Pest zip: 2143 country: Hungary name: Robert J. Kirschner role: PRINCIPAL_INVESTIGATOR lat: 47.54757 lon: 19.26247 facility: Óbudai Egészségügyi Centrum city: Budapest zip: 1036 country: Hungary name: Alexandra Marian role: PRINCIPAL_INVESTIGATOR lat: 47.49801 lon: 19.03991 facility: PVN Kutató Kft city: Budapest zip: 1102 country: Hungary name: Judit Nádas role: PRINCIPAL_INVESTIGATOR lat: 47.49801 lon: 19.03991 facility: Privát Doktor Egészségügyi Zrt city: Budapest zip: 1132 country: Hungary name: Andras R Vertes role: PRINCIPAL_INVESTIGATOR lat: 47.49801 lon: 19.03991 facility: Újpesti Egészségügyi Nonprofit Kft city: Budapest zip: H-1046 country: Hungary name: Eva Judit Takacs role: PRINCIPAL_INVESTIGATOR lat: 47.49801 lon: 19.03991 facility: G.B. Pant Institute of Postgraduate Medical Education & Research city: New Delhi state: Delhi zip: 110002 country: India name: Vimal Mehta role: PRINCIPAL_INVESTIGATOR lat: 28.63576 lon: 77.22445 facility: Shri Bachubhai Dahyabhai Mehta Mahavir Heart Institute city: Surat state: Gujarat zip: 395002 country: India name: Atul Damodar Abhyankar role: PRINCIPAL_INVESTIGATOR lat: 21.19594 lon: 72.83023 facility: Life Care Hospital and Research Centre city: Bangalore state: Karnataka zip: 560092 country: India name: Prasad M Bhat role: PRINCIPAL_INVESTIGATOR lat: 12.97194 lon: 77.59369 facility: Manipal Hospitals city: Mysore state: Karnataka zip: 570015 country: India name: Chakrabhavi Keshavamurthy role: PRINCIPAL_INVESTIGATOR lat: 12.29791 lon: 76.63925 facility: Government Medical College - Kozhikode city: Kozhikode state: Kerala zip: 673008 country: India name: Neeraj Manikath role: PRINCIPAL_INVESTIGATOR lat: 11.24802 lon: 75.7804 facility: Shrikrishna Hrudayalaya And Critical Care Center city: Nagpur state: Maharashtra zip: 440012 country: India name: Mahesh Chandumal Fulwani role: PRINCIPAL_INVESTIGATOR lat: 21.14631 lon: 79.08491 facility: All India Institute of Medical Sciences (AIIMS) - Nagpur city: Nagpur state: Maharashtra zip: 441108 country: India name: Amol Bhawane role: PRINCIPAL_INVESTIGATOR lat: 21.14631 lon: 79.08491 facility: All India Institute of Medical Sciences city: Bhubaneswar state: Odisha zip: 751019 country: India name: Saroj Kumar Sahoo role: PRINCIPAL_INVESTIGATOR lat: 20.27241 lon: 85.83385 facility: S C B Medical College and Hospital city: Cuttack state: Odisha zip: 753001 country: India name: Dipak Ranjan Das role: PRINCIPAL_INVESTIGATOR lat: 20.46497 lon: 85.87927 facility: Medway Hospitals - Kodambakkam city: Chennai state: Tamil Nadu zip: 600024 country: India name: Jai Shankar Krishnamoorthy role: PRINCIPAL_INVESTIGATOR lat: 13.08784 lon: 80.27847 facility: Motilal Nehru Medical College Hospital city: Allahabad state: Uttar Pradesh zip: 211002 country: India name: Santosh kumar maurya role: PRINCIPAL_INVESTIGATOR lat: 25.44478 lon: 81.84322 facility: K care Hospital city: Kanpur state: Uttar Pradesh zip: 208001 country: India name: Amit Kumar Gupta role: PRINCIPAL_INVESTIGATOR lat: 26.46523 lon: 80.34975 facility: LPS Institute of Cardiology city: Kanpur state: Uttar Pradesh zip: 208002 country: India name: Awadhesh Kumar Sharma role: PRINCIPAL_INVESTIGATOR lat: 26.46523 lon: 80.34975 facility: Dr. Ram Manohar Lohia Institute of Medical Sciences city: Lucknow state: Uttar Pradesh zip: 226010 country: India name: Naveen Jamwal role: PRINCIPAL_INVESTIGATOR lat: 26.83928 lon: 80.92313 facility: Shri Mahant Indiresh Hospital city: Dehradun state: Uttarakhand zip: 248001 country: India name: Vivek Ruhela role: PRINCIPAL_INVESTIGATOR lat: 30.32295 lon: 78.03168 facility: Diabetes Medical Center city: Tel Aviv state: HaMerkaz zip: 6937947 country: Israel name: Maya Ish Shalom role: PRINCIPAL_INVESTIGATOR lat: 32.08088 lon: 34.78057 facility: Centro de Investigacion en Artritis y Osteoporosis SC city: Mexicali state: Baja California zip: 21200 country: Mexico name: Francisco Fidencio Cons Molina role: PRINCIPAL_INVESTIGATOR lat: 32.62781 lon: -115.45446 facility: Centro de Investigacion Cardiovascular y Metabólica city: Tijuana state: Baja California zip: 22500 country: Mexico name: Pedro Fajardo Campos role: PRINCIPAL_INVESTIGATOR lat: 32.5027 lon: -117.00371 facility: Cryptex Investigación Clínica S.A. de C.V. city: Cuauhtémoc, Ciudad De México state: Distrito Federal zip: 06100 country: Mexico name: Juan Alfredo Tamayo y Orozco role: PRINCIPAL_INVESTIGATOR facility: RM Pharma Specialists city: Mexico City state: Distrito Federal zip: 03100 country: Mexico name: Mariana Zolandi Crespo role: PRINCIPAL_INVESTIGATOR lat: 19.42847 lon: -99.12766 facility: Clínicos Asociados BOCM city: Mexico City state: Distrito Federal zip: 03300 country: Mexico name: Israel Olvera-Alvarez role: PRINCIPAL_INVESTIGATOR lat: 19.42847 lon: -99.12766 facility: Hospital de Jésus, I.A.P. city: Mexico City state: Distrito Federal zip: 06090 country: Mexico name: Efrain Villeda Espinosa role: PRINCIPAL_INVESTIGATOR lat: 19.42847 lon: -99.12766 facility: Clinica Omega city: Mexico City state: Distrito Federal zip: 06700 country: Mexico name: Jose Hector Sanchez Mijangos role: PRINCIPAL_INVESTIGATOR lat: 19.42847 lon: -99.12766 facility: Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares city: Mexico City state: Distrito Federal zip: 11650 country: Mexico name: Melchor Alpizar Salazar role: PRINCIPAL_INVESTIGATOR lat: 19.42847 lon: -99.12766 facility: ProcliniQ Investigación Clínica SA de CV city: Mexico City state: Distrito Federal zip: 14050 country: Mexico name: Mauricio Lopez Meneses role: PRINCIPAL_INVESTIGATOR lat: 19.42847 lon: -99.12766 facility: Clinstile, S.A. de C.V. city: Mexico state: Distrito Federal zip: 06700 country: Mexico name: Vicente Eduardo Ruiz Ruiz role: PRINCIPAL_INVESTIGATOR lat: 19.42847 lon: -99.12766 facility: Medimanage Research city: Tlalpan state: Distrito Federal zip: 14050 country: Mexico name: Olynka Vega-Vega role: PRINCIPAL_INVESTIGATOR lat: 19.29513 lon: -99.16206 facility: Instituto Cardiovascular de León S.C. city: León state: Guanajuato zip: 37520 country: Mexico name: Luis Adolfo Venegas Carrillo role: PRINCIPAL_INVESTIGATOR lat: 21.12908 lon: -101.67374 facility: Centro de Atencion al Diabetico Actopan city: Actopan state: Hidalgo zip: 42500 country: Mexico name: Marco Antonio Morales de Teresa role: PRINCIPAL_INVESTIGATOR lat: 20.26961 lon: -98.94377 facility: Centro de Investigacion Medica Integral city: Guadalajara state: Jalisco zip: 44160 country: Mexico name: Carlos Alejandro Stobschinski de Alba role: PRINCIPAL_INVESTIGATOR lat: 20.66682 lon: -103.39182 facility: Centro de Investigación Clínica y Medicina Traslacional (CIMeT) city: Guadalajara state: Jalisco zip: 44340 country: Mexico name: Ramon Medina-Gonzalez role: PRINCIPAL_INVESTIGATOR lat: 20.66682 lon: -103.39182 facility: Private Practice - Dr. Arechavaleta Granell Maria del Rosario city: Guadalajara state: Jalisco zip: 44670 country: Mexico name: Maria Del Rosario Arechavaleta Granell role: PRINCIPAL_INVESTIGATOR lat: 20.66682 lon: -103.39182 facility: Unidad de Investigación Clínica y Atención Médica HEPA city: Guadalajara state: Jalisco zip: 44670 country: Mexico name: Marisol Herrera Marmolejo role: PRINCIPAL_INVESTIGATOR lat: 20.66682 lon: -103.39182 facility: Virgen Cardiovascular Research SC city: Guadalajara state: Jalisco zip: 44670 country: Mexico name: Luis Ramon Virgen Carrillo role: PRINCIPAL_INVESTIGATOR lat: 20.66682 lon: -103.39182 facility: CINVEC Medica city: Guadalajara state: Jalisco zip: 44690 country: Mexico name: Ricardo Orozco Castellanos role: PRINCIPAL_INVESTIGATOR lat: 20.66682 lon: -103.39182 facility: Clinica de Enfermedades Crónicas y de Procedimientos Especiales city: Morelia state: Michoacán zip: 58249 country: Mexico name: Helios Vega role: PRINCIPAL_INVESTIGATOR lat: 19.70078 lon: -101.18443 facility: Instituto de Diabetes, Obesidad y Nutricion city: Cuernavaca state: Morelos zip: 62250 country: Mexico name: Leobardo Sauque Reyna role: PRINCIPAL_INVESTIGATOR lat: 18.9261 lon: -99.23075 facility: PanAmerican Clinical Research - Cuernavaca city: Cuernavaca state: Morelos zip: 62290 country: Mexico name: Yovani Robles-Abarca role: PRINCIPAL_INVESTIGATOR lat: 18.9261 lon: -99.23075 facility: Investigación Nefrológica city: Cuernavaca state: Morelos zip: 62448 country: Mexico name: MARIA MAGDALENA LAFRAGUA role: PRINCIPAL_INVESTIGATOR lat: 18.9261 lon: -99.23075 facility: Servicios de Oncología Medica Integral - Monterrey - José Benitez city: Monterrey state: Nuevo León zip: 64040 country: Mexico name: Jesus Zacarias Villarreal role: PRINCIPAL_INVESTIGATOR lat: 25.67507 lon: -100.31847 facility: Cardiolink Clin Trials city: Monterrey state: Nuevo León zip: 64060 country: Mexico name: Elías García role: PRINCIPAL_INVESTIGATOR lat: 25.67507 lon: -100.31847 facility: IMED Internal Medicine Clin Trials city: Monterrey state: Nuevo León zip: 64060 country: Mexico name: Jose Angel Garza Ruiz role: PRINCIPAL_INVESTIGATOR lat: 25.67507 lon: -100.31847 facility: Unidad biomedica avanzada monterrey city: Monterrey state: Nuevo León zip: 64460 country: Mexico name: Raymundo Garcia Reza role: PRINCIPAL_INVESTIGATOR lat: 25.67507 lon: -100.31847 facility: Clínica García Flores SC city: Monterrey state: Nuevo León zip: 64610 country: Mexico name: Pedro Alberto Garcia role: PRINCIPAL_INVESTIGATOR lat: 25.67507 lon: -100.31847 facility: Centro de investigación y control metabólico city: Monterrey state: Nuevo León zip: 66465 country: Mexico name: Ramiro Guadalupe Banda Elizondo role: PRINCIPAL_INVESTIGATOR lat: 25.67507 lon: -100.31847 facility: Centro de Investigacion Clinica de Oaxaca city: Oaxaca de Juarez state: Oaxaca zip: 68020 country: Mexico name: Jesus Antonio Perez Ríos role: PRINCIPAL_INVESTIGATOR lat: 17.06542 lon: -96.72365 facility: Centro Para El Desarrollo de La Medicina Y de Asistencia Medica Especializada S.C. city: Culiacan state: Sinaloa zip: 80230 country: Mexico name: Manuel Odin de los Rios Ibarra role: PRINCIPAL_INVESTIGATOR lat: 24.79032 lon: -107.38782 facility: Consultorio de Medicina Especilizada del Sector Privado city: Xalapa state: Veracruz zip: 91193 country: Mexico name: Enrique Lopez Rosas role: PRINCIPAL_INVESTIGATOR lat: 19.53124 lon: -96.91589 facility: Medical Care and Research SA de CV city: Merida state: Yucatán zip: 97070 country: Mexico name: Carlos Eduardo Medina role: PRINCIPAL_INVESTIGATOR lat: 20.97537 lon: -89.61696 facility: EME RED Hospitalaria city: Mérida state: Yucatán zip: 97000 country: Mexico name: Hugo Antonio Laviada Molina role: PRINCIPAL_INVESTIGATOR lat: 20.97537 lon: -89.61696 facility: Fundación Cardiovascular de Aguascalientes A.C. city: Aguascalientes zip: 20230 country: Mexico name: Edmundo Alfredo Bayram Llamas role: PRINCIPAL_INVESTIGATOR lat: 21.88234 lon: -102.28259 facility: Enclifar Ensayos Clínicos Farmacológicos Sc city: Chihuahua zip: 31110 country: Mexico name: Luis Alejandro Nevarez role: PRINCIPAL_INVESTIGATOR lat: 28.63528 lon: -106.08889 facility: Instituto de Investigaciones Aplicadas a la Neurociencia A.C. city: Durango zip: 34000 country: Mexico name: Hector Eduardo Delgado Gomez role: PRINCIPAL_INVESTIGATOR lat: 24.02032 lon: -104.65756 facility: Lahoja. Asociacion Para La Investigacion Y La Farmacovigilancia city: Durango zip: 34000 country: Mexico name: Juan Carlos Núñez Fragoso role: PRINCIPAL_INVESTIGATOR lat: 24.02032 lon: -104.65756 facility: Boca Clinical Trials Mexico SC city: Puebla zip: 72160 country: Mexico name: Carlos Gonzalez Parra role: PRINCIPAL_INVESTIGATOR lat: 19.03793 lon: -98.20346 facility: Centro de Estudios Clínicos de Querétaro (CECLIQ) city: Querétaro zip: 76000 country: Mexico name: Marco Antonio Alcocer Gamba role: PRINCIPAL_INVESTIGATOR facility: PanAmerican Clinical Research - Querétaro - Avenida Antea city: Querétaro zip: 76100 country: Mexico name: Juan Villagordoa Mesa role: PRINCIPAL_INVESTIGATOR facility: Centro de Atención e Investigación Cardiovascular del Potosí city: San Luis Potosí zip: 78200 country: Mexico name: José Luis Arenas León role: PRINCIPAL_INVESTIGATOR lat: 22.14982 lon: -100.97916 facility: Instituto Veracruzano en Investigación Clínica S.C. city: Veracruz zip: 91851 country: Mexico name: Rosa Isela Luna Ceballos role: PRINCIPAL_INVESTIGATOR lat: 19.18095 lon: -96.1429 facility: FAICIC S. de R.L. de C.V. city: Veracruz zip: 91900 country: Mexico name: Sandro Fabricio Avila role: PRINCIPAL_INVESTIGATOR lat: 19.18095 lon: -96.1429 facility: Arké SMO S.A de C.V city: Veracruz zip: 91910 country: Mexico name: Luis Horacio Aguilar Espinoza role: PRINCIPAL_INVESTIGATOR lat: 19.18095 lon: -96.1429 facility: Emotional Brain FlevoResearch city: Almere state: Flevoland zip: 1311 RL country: Netherlands name: Mazin Alhakim role: PRINCIPAL_INVESTIGATOR lat: 52.37535 lon: 5.25295 facility: Medisch Centrum Thomsonplein city: The Hague state: Zuid-Holland zip: 2565 KV country: Netherlands name: Boudewijn Alexander Hoek role: PRINCIPAL_INVESTIGATOR lat: 52.07667 lon: 4.29861 facility: Huisartsenpraktijk Broekman city: Zwijndrecht state: Zuid-Holland zip: 3333 GZ country: Netherlands name: Matthijs Broekman role: PRINCIPAL_INVESTIGATOR lat: 51.8175 lon: 4.63333 facility: Huisartsenpraktijk Disha city: Den Haag zip: 2572 GM country: Netherlands name: Ravee Rambharose role: PRINCIPAL_INVESTIGATOR lat: 52.07667 lon: 4.29861 facility: Dokters van Nederhoven city: Zwijndrecht zip: 3334 SB country: Netherlands name: Ralph Verkleij role: PRINCIPAL_INVESTIGATOR lat: 51.8175 lon: 4.63333 facility: NZOZ Centurm Medyczne SERAFIN-MED city: Zarow state: Dolnośląskie zip: 58-130 country: Poland name: Ryszard Serafin role: PRINCIPAL_INVESTIGATOR lat: 50.94116 lon: 16.49466 facility: NZOZ Centrum Medyczne KERmed city: Bydgoszcz state: Kujawsko-pomorskie zip: 85-231 country: Poland name: Tomasz Lugowski role: PRINCIPAL_INVESTIGATOR lat: 53.1235 lon: 18.00762 facility: INTERCOR city: Bydgoszcz state: Kujawsko-pomorskie zip: 85-605 country: Poland name: Grzegorz Grzesk role: PRINCIPAL_INVESTIGATOR lat: 53.1235 lon: 18.00762 facility: CenterMed Lublin NZOZ city: Lublin state: Lubelskie zip: 20-044 country: Poland name: Grzegorz Drelich role: PRINCIPAL_INVESTIGATOR lat: 51.25 lon: 22.56667 facility: Ekamed city: Lublin state: Lubelskie zip: 20-718 country: Poland name: Ewa Maria Szyprowska role: PRINCIPAL_INVESTIGATOR lat: 51.25 lon: 22.56667 facility: Balsam Medica city: Warsaw state: Mazowieckie zip: 01-249 country: Poland name: Marcin Grabowski role: PRINCIPAL_INVESTIGATOR lat: 52.22977 lon: 21.01178 facility: Polsko-Amerykańskie Kliniki Serca PAKS Małopolskie Centrum Sercowo-Naczyniowe city: Chrzanow state: Małopolskie zip: 32-500 country: Poland name: Aleksander Zurakowski role: PRINCIPAL_INVESTIGATOR lat: 50.13546 lon: 19.40203 facility: NZOZ Diab-Endo-Met city: Krakow state: Małopolskie zip: 31-261 country: Poland name: Joanna Mirocka role: PRINCIPAL_INVESTIGATOR lat: 50.06143 lon: 19.93658 facility: Centrum Szybkiej Diagnostyki Kardiologicznej "Kardiomed" M. Żabówka E. Żabówka city: Tarnow state: Małopolskie zip: 33-100 country: Poland name: Maciej Stanislaw Zabowka role: PRINCIPAL_INVESTIGATOR lat: 50.01381 lon: 20.98698 facility: EndoPractica city: Opole state: Opolskie zip: 45-301 country: Poland name: Agata Bronisz role: PRINCIPAL_INVESTIGATOR lat: 50.67211 lon: 17.92533 facility: KLIMED Marek Klimkiewicz city: Bialystok state: Podlaskie zip: 15-704 country: Poland name: Irena Glowinska role: PRINCIPAL_INVESTIGATOR lat: 53.13333 lon: 23.16433 facility: Centrum Kliniczno-Badawcze city: Elblag state: Warmińsko-mazurskie zip: 82-300 country: Poland name: Bozena Gornikiewicz-Brzezicka role: PRINCIPAL_INVESTIGATOR lat: 54.1522 lon: 19.40884 facility: Poliklinika Kardiologiczna Serce city: Leszno state: Wielkopolskie zip: 64-100 country: Poland name: Witold Piotrowski role: PRINCIPAL_INVESTIGATOR lat: 51.84034 lon: 16.57494 facility: Centrum Zdrowia Metabolicznego Pawel Bogdanski city: Poznań state: Wielkopolskie zip: 60-589 country: Poland name: Pawel Bogdanski role: PRINCIPAL_INVESTIGATOR lat: 52.40692 lon: 16.92993 facility: Pro Salus Centrum Medyczne city: Lodz state: Łódzkie zip: 91-473 country: Poland name: Marcin Ojrzanowski role: PRINCIPAL_INVESTIGATOR lat: 51.75 lon: 19.46667 facility: Polsko-Amerykańskie Kliniki Serca II Oddział Kardiologiczny city: Bielsko-Biala state: Śląskie zip: 43-300 country: Poland name: Krzysztof Milewski role: PRINCIPAL_INVESTIGATOR lat: 49.82245 lon: 19.04686 facility: Diab Serwis Popenda Spółka Jawna city: Chorzow state: Śląskie zip: 41-500 country: Poland name: Grazyna Popenda role: PRINCIPAL_INVESTIGATOR lat: 50.30582 lon: 18.9742 facility: Polsko-Amerykańskie Kliniki Serca city: Tychy state: Śląskie zip: 43-100 country: Poland name: Adam Janas role: PRINCIPAL_INVESTIGATOR lat: 50.13717 lon: 18.96641 facility: Advanced Clinical Research, LLC city: Bayamón zip: 00959 country: Puerto Rico name: Angel Luis Comulada-Rivera role: PRINCIPAL_INVESTIGATOR lat: 18.39856 lon: -66.15572 facility: IN-DIA city: Lucenec state: Banskobystrický Kraj zip: 984 01 country: Slovakia name: Livia Tomasova role: PRINCIPAL_INVESTIGATOR lat: 48.33249 lon: 19.66708 facility: MUDr. Judita Gondova city: Poltar state: Banskobystrický Kraj zip: 987 01 country: Slovakia name: Judita Gondova role: PRINCIPAL_INVESTIGATOR lat: 48.43094 lon: 19.79408 facility: ENRIN, s.r.o. city: Rimavská Sobota state: Banskobystrický Kraj zip: 979 01 country: Slovakia name: Jana Horvath Bercikova role: PRINCIPAL_INVESTIGATOR lat: 48.38284 lon: 20.02239 facility: Sin Azucar city: Malacky state: Bratislavský Kraj zip: 901 01 country: Slovakia name: Barbora Zobokova role: PRINCIPAL_INVESTIGATOR lat: 48.43604 lon: 17.02188 facility: NOVUM+ city: Kosice state: Košický Kraj zip: 040 01 country: Slovakia name: Viera Donicova role: PRINCIPAL_INVESTIGATOR lat: 48.71395 lon: 21.25808 facility: Tatratrial s.r.o. city: Rožňava state: Košický Kraj zip: 04801 country: Slovakia name: Beata Lachova role: PRINCIPAL_INVESTIGATOR lat: 48.66009 lon: 20.53758 facility: Areteus s.r.o. city: Trebisov state: Košický Kraj zip: 075 01 country: Slovakia name: Dasa Skripova role: PRINCIPAL_INVESTIGATOR lat: 48.62858 lon: 21.71954 facility: Fakultná nemocnica Nitra city: Nitra state: Nitriansky Kraj zip: 950 01 country: Slovakia name: Peter Minarik role: PRINCIPAL_INVESTIGATOR lat: 48.30763 lon: 18.08453 facility: Funkystuff city: Nove Zamky state: Nitriansky Kraj zip: 940 02 country: Slovakia name: Miriam Teplanova role: PRINCIPAL_INVESTIGATOR lat: 47.98544 lon: 18.16195 facility: MEDIKALS city: Piešťany state: Trnavský Kraj zip: 921 01 country: Slovakia name: Slavka Kalinova role: PRINCIPAL_INVESTIGATOR lat: 48.59479 lon: 17.82591 facility: ENDIAMED s.r.o city: Dolny Kubin state: Žilinský Kraj zip: 026 01 country: Slovakia name: Jan Truban role: PRINCIPAL_INVESTIGATOR lat: 49.20983 lon: 19.30341 facility: JM-Interna s.r.o city: Dolny Kubin state: Žilinský Kraj zip: 02601 country: Slovakia name: Jan Micik role: PRINCIPAL_INVESTIGATOR lat: 49.20983 lon: 19.30341 facility: NEDÚ - Národný endokrinologický a diabetologický ústav n.o. city: Lubochna state: Žilinský Kraj zip: 034 91 country: Slovakia name: Emil Martinka role: PRINCIPAL_INVESTIGATOR lat: 49.12011 lon: 19.16891 facility: AMBORA s.r.o. Interna ambulancia city: Martin state: Žilinský Kraj zip: 036 01 country: Slovakia name: Boris Raska role: PRINCIPAL_INVESTIGATOR lat: 49.06651 lon: 18.92399 facility: MediPrax, s.r.o. city: Trstena state: Žilinský Kraj zip: 028 01 country: Slovakia name: Ivana Škerdová role: PRINCIPAL_INVESTIGATOR lat: 49.36101 lon: 19.61249 facility: B-Medical, s.r.o. city: Tvrdošín state: Žilinský Kraj zip: 027 44 country: Slovakia name: Maria Balekova role: PRINCIPAL_INVESTIGATOR lat: 49.337 lon: 19.556 facility: IRIDIA city: Vrutky state: Žilinský Kraj zip: 038 61 country: Slovakia name: Radovan Plasil role: PRINCIPAL_INVESTIGATOR lat: 49.11328 lon: 18.91714 facility: Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE) city: Sevilla zip: 41003 country: Spain name: Alberto Aliaga Verdugo role: PRINCIPAL_INVESTIGATOR lat: 37.38283 lon: -5.97317 facility: Eskisehir Osmangazi University city: Eskisehir state: Eskişehir zip: 26480 country: Turkey name: Yuksel Cavusoglu role: PRINCIPAL_INVESTIGATOR lat: 39.77667 lon: 30.52056 facility: Istanbul Universitesi Cerrahpasa city: Istanbul- Fatih state: İstanbul zip: 34098 country: Turkey name: Nurhan Seyahi role: PRINCIPAL_INVESTIGATOR facility: Necmettin Erbakan University Meram Medical Faculty ; Internal Diseases city: Meram state: Konya zip: 42080 country: Turkey name: Kultigin Turkmen role: PRINCIPAL_INVESTIGATOR lat: 37.82985 lon: 32.46777 facility: Adana Sehir Egitim ve Arastirma Hastanesi city: Adana zip: 01370 country: Turkey name: Ibrahim Halil Kurt role: PRINCIPAL_INVESTIGATOR lat: 37.00167 lon: 35.32889 facility: Ankara Bilkent Şehir Hastanesi city: Ankara zip: 06800 country: Turkey name: Burcu Demirkan role: PRINCIPAL_INVESTIGATOR lat: 39.91987 lon: 32.85427 facility: T.C. Saglik Bakanligi - Hitit Universitesi Corum Egitim ve Arastirma Hastanesi city: Corum zip: 19040 country: Turkey name: Lütfü Bekar role: PRINCIPAL_INVESTIGATOR lat: 40.54889 lon: 34.95333 facility: Gaziantep Universitesi Sahinbey Arastirma ve Uygulama Hastanesi city: Gaziantep zip: 27310 country: Turkey name: Fatih Mehmet Erdur role: PRINCIPAL_INVESTIGATOR lat: 37.05944 lon: 37.3825 facility: Dr. Siyami Ersek Göğüs Kalp Ve Damar Cerrahisi Eğitim Ve Araştırma Hastanesi city: Istanbul zip: 34668 country: Turkey name: Baris Gungor role: PRINCIPAL_INVESTIGATOR lat: 41.01384 lon: 28.94966 facility: Kartal Koşuyolu Yüksek İhtisas Eğitim ve Araştirma Hastanesi city: Istanbul zip: 34865 country: Turkey name: Gokhan Alici role: PRINCIPAL_INVESTIGATOR lat: 41.01384 lon: 28.94966 facility: Erciyes Universitesi Tıp Fakultesi Hastaneleri city: Kayseri country: Turkey name: Ismail Kocyigit role: PRINCIPAL_INVESTIGATOR lat: 38.73222 lon: 35.48528 facility: Ophthalmology city: Kocaeli zip: 41380 country: Turkey name: Necmi Eren role: PRINCIPAL_INVESTIGATOR lat: 39.62497 lon: 27.51145 facility: T.C. Saglik Bakanligi - Dumlupinar Universitesi Kutahya Evliya Celebi Egitim ve Arastirma Hastanesi city: Kütahya zip: 43100 country: Turkey name: Taner Sen role: PRINCIPAL_INVESTIGATOR lat: 39.42417 lon: 29.98333 facility: Homecroft Surgery city: Redruth state: Cornwall zip: TR16 4ET country: United Kingdom name: Mark Simon Danielsen role: PRINCIPAL_INVESTIGATOR lat: 50.23315 lon: -5.22434 facility: Rame Medical Ltd city: Torpoint state: Cornwall zip: PL11 2TB country: United Kingdom name: Lawrence Barnes role: PRINCIPAL_INVESTIGATOR lat: 50.37505 lon: -4.19566 facility: FutureMeds - Birmingham city: Birmingham zip: B21 9RY country: United Kingdom name: Tehmina Ahmed role: PRINCIPAL_INVESTIGATOR lat: 52.48142 lon: -1.89983 hasResults: False |
<|newrecord|> nctId: NCT06383377 id: Pre-market parallel study briefTitle: Evaluation of Performance, Safety and Benefit of the Wishbone HA as Bone Graft Substitute, a Pre-market Clinical Investigation overallStatus: RECRUITING date: 2024-04-26 date: 2025-03-31 date: 2030-03-31 date: 2024-04-25 date: 2024-04-25 name: Wishbone SA class: INDUSTRY name: EVAMED name: Pharmalex name: Advimago briefSummary: This investigation is a pre-market, prospective, multi-center, randomized, single blinded, parallel controlled clinical investigation performed in at least 5 clinical centers for confirmatory purposes of the use of WHA as intended in the filling of extraction sockets to enhance preservation of the alveolar socket. conditions: Bone Regeneration conditions: Safety Issues studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The parallel group will be treated with the product Bio-Oss® in a 1:1 randomization. Bio- Oss® is a natural bone mineral of bovine origin. Bio-Oss® is available as granules of spongious bone. Sterilization of Bio-Oss® is carried out by irradiation. Bio-Oss® has a macro- and microporous structure similar to human spongious bone. Bio-Oss® supports the in-growth of new bone at the implantation site by serving as a stable scaffold for osteoblasts; over time it is subject to the physiological remodeling process. Bio-Oss® is slowly resorbable, depending on the physiological environment of the individual patient, or integrated into the host bone. The highly purified osteoconductive mineral structure is produced from natural bone in a multistage purification process, adhering to the strictest safety regulations. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Patients will not be informed of their randomization assignment until the 1 year post implant placement follow-up visit. At this timepoint, the primary endpoint will have been achieved (at the implant placement visit) as well as the majority of the secondary endpoints. After the bone grafting surgery, all patients will receive an identic implant cart that does not break the blinding of the study. 1 year after implant placement, the patients will receive their definitive implant cart. whoMasked: PARTICIPANT count: 96 type: ESTIMATED name: Tooth extraction and bone graft procedure measure: Bone reconstruction as measured by CBCT (in mm) after bone grafting procedure. measure: Assessment of the bone density at implant placement. measure: Evaluation of the implant primary stability. measure: Assessment of the implant osteointegration after implant placement measure: Implant survival rate and success evaluated at 3-, 6- and 12-months and 3- and 5- To evaluate implant survival and success 3-, 6- and 12- months and 3- and 5-years after implant placement measure: Collection of all adverse events (AEs) related to the device and/or procedure, and assessment of incidence, type, severity, seriousness measure: Evaluation of patient satisfaction at 6- and 12-months after implant placement using questionnaire. measure: Evaluation of the peri-implant marginal tissue health status at 6 and 12 months after implant placement. measure: Evaluation of the evolution of the interproximal bone level 3- and 12-months after implant placement. sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Clinique de la Source DentalMe status: RECRUITING city: Louvain-la-Neuve state: Brabant Wallon zip: 1348 country: Belgium name: Sami El Masri role: CONTACT email: [email protected] name: Laurane Pansaers role: SUB_INVESTIGATOR lat: 50.66829 lon: 4.61443 facility: Cabinet Debaty-Techy status: RECRUITING city: Aubel state: Liège zip: 4880 country: Belgium name: Bertrand Debaty role: CONTACT email: [email protected] lat: 50.70189 lon: 5.85812 facility: Clinique du Faubourg DentalMe status: RECRUITING city: Chaudfontaine state: Liège zip: 4053 country: Belgium name: Souheil Salem role: CONTACT email: [email protected] lat: 50.5828 lon: 5.6341 facility: Centre Hospitalier Université de Liège status: RECRUITING city: Liège zip: 4000 country: Belgium name: Bruno De Carvalho role: CONTACT email: mailto:[email protected] name: Lemmy Liegeois role: SUB_INVESTIGATOR name: Gilles Szotek role: SUB_INVESTIGATOR lat: 50.63373 lon: 5.56749 facility: Centre Oxalys status: RECRUITING city: Namur zip: 5020 country: Belgium name: Adrien Bolette role: CONTACT email: [email protected] lat: 50.4669 lon: 4.86746 hasResults: False |
<|newrecord|> nctId: NCT06383364 id: SHS-Pharm - 1 - 2024 briefTitle: The Effect of a Medication Coordinator on the Quality of Patients Medication Treatment acronym: MEDCOOR overallStatus: ENROLLING_BY_INVITATION date: 2024-05-01 date: 2025-06-01 date: 2025-06-01 date: 2024-04-25 date: 2024-04-25 name: University of Southern Denmark class: OTHER briefSummary: To examine the effect of a Medication Coordinator, who facilitates medication reviews in close collaboration with patients using My Medication Plan to reduce the risk of post-hospital inappropriate medication usage. conditions: Medication Administered in Error studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: SINGLE whoMasked: CARE_PROVIDER count: 140 type: ESTIMATED name: Medication Coordinator measure: Reduction of potentially inappropriate medication according to Potentially Inappropriate Medication List measure: Evaluation of patients experiences quality of life with the EQ-5D and EQ-VAS. measure: Evaluation of patients experienced quality of life with visual analogue scale (VAS). measure: Evaluation of patients experienced treatment burden with the questionnaire Multimorbidity treatment burden questionnaire (MTBQ). measure: Evaluation of patients experienced medication burden with visual analogue scale (VAS). measure: Patient readmission 30 days after hospital discharge measure: Patient contact to the ward 30 days after hospital discharge sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sygehus Sønderjylland city: Aabenraa state: Southern Denmark zip: 6200 country: Denmark lat: 55.04434 lon: 9.41741 hasResults: False |
<|newrecord|> nctId: NCT06383351 id: BQ001 briefTitle: Patients' Illness Perception of Peri-implant Diseases. A Cross-sectional Study overallStatus: RECRUITING date: 2024-04-16 date: 2024-05 date: 2024-05 date: 2024-04-25 date: 2024-04-25 name: University of Siena class: OTHER briefSummary: Despite extensive research on periodontitis, little attention has been given to the symptoms and perception of peri-implant diseases and their impact on oral health-related quality of life. The study aims to assess patient perception of these diseases and their impact on quality of life through a cross-sectional observational study. Patients will be recruited from the Unit of Periodontics at "Le Scotte" University Hospital and will undergo diagnosis followed by questionnaire assessments. No follow-up visits are planned, and validated questionnaires will be administered to evaluate perception and impact on quality of life. Study procedures will include recording biometric peri-implant parameters and administering questionnaires such as the Brief Illness Perception Questionnaire (BIPQ) and Oral Health Impact Profile-14 (OHIP-14). conditions: Peri-implant Mucositis conditions: Perception conditions: Survey conditions: Questionnaires conditions: Peri-Implantitis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 150 type: ESTIMATED name: Questionnaire measure: Assessment of patient's perception of their peri-implant disease through the Brief Illness Perception Questionnaire (Brief IPQ) measure: Assessment of peri-implant disease's impact on the oral health-related quality of life through the Oral Health Impact Profile 14. sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: AOUS status: RECRUITING city: Siena zip: 53100 country: Italy name: Nicola Discepoli role: CONTACT phone: 3395256148 email: [email protected] lat: 43.31822 lon: 11.33064 hasResults: False |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.